Comparison of experimental and calculated M-ligand bond lengths (Å) of complexes (1–3).
\r\n\tIt is a relatively simple process and a standard tool in any industry. Because of the versatility of the titration techniques, nearly all aspects of society depend on various forms of titration to analyze key chemical compounds.
\r\n\tThe aims of this book is to provide the reader with an up-to-date coverage of experimental and theoretical aspects related to titration techniques used in environmental, pharmaceutical, biomedical and food sciences.
Alzheimer disease (AD), was first recognized in the early 1900’s by Alois Alzheimer, a German psychiatrist and neuro pathologist and named after him (Fig.1). Auguste Deter, in 1902 is a reported patient of Dr. Alois (Fig.2). AD is the most common form of dementia affecting millions of the geriatric population worldwide, mostly those above 65-85 yrs of age. Women are more commonly affected than man [1]. Alzheimer currently afflicts about 5.2 million Americans and with the rapid escalation of the prevalence of the disease, the figure is expected to double by 2020. According to WHO, there are about 18 million people worldwide with AD, the figure will be projected to nearly double by 2025 to 34 million. Developing countries like India and China will be among the countries worst hit by AD due to ageing of the population and likely some genetic factors. In 2000, India had 3.5 million Alzheimer patients, however with the fast graying of population and growth rate being fastest in the 80+ segment of the society, the number of Alzheimer patients have been growing at a phenomenal rate [2]. This neurodegenerative fatal brain disorder generally begins in late life and disease progression is gradual and continuous, the longevity of a patient is about 8-10 yrs after symptoms appear. The disease conditions range from mild, moderate to severe; in mild conditions patients have some functional impairments, in moderate conditions there’s a dependence on care givers for some important daily activities, in severe conditions there is complete neuronal and memory loss, motor impairment making the patient absolutely dependent on care givers. Age related behavioral changes and symptoms of Alzheimer should not be confused.
Dr. Alois Alzheimer(1864-1915)
Auguste Deter (1902), patient of Dr. Alois
Typical clinical symptoms of Alzheimer include: signs of progressive memory loss disturbing daily activities, difficulty in completing daily activities, poor judgment, vision problems, sudden changes in mood and personality, self withdrawal from hobbies or social contacts, loss of cognition, loss of coordination, etc. Ageing is the greatest risk factor of AD though Alzheimer is not a normal part of aging since people below 65yrs of age can also develop AD referred to as ‘younger or early onset’ [1,2]. The differences between a normal aged brain and the brain of an Alzheimer patient have been depicted in Fig.3. Other prominent risk factors in AD include family history, heredity (genetics), environmental factors. A genetic factor in late onset AD is ApoE ε4. The gene for apolipoprotein E (ApoE) on chromosome 19 has gained much recent attention in the pathogenesis of AD. ApoE is a protein modulator of phospholipid transport that might have a role in synaptic remodeling. ApoE has three common alleles, ApoE ε2, ε3, and ε4, which are expressed in varying amounts in the normal person. It is the ApoE ε4 genotype that is associated with the risk of AD. Everyone inherits one form of APoE gene from each parent; those who receive ApoE ε4 gene are at the risk of developing AD than those who receive ApoE ε2, ApoE ε3. Individuals who inherit two ApoE ε4 genes are at even higher risk; however inheriting one or two copies of genes does not gurantee that the individual will develop Alzheimer [3,4,5]. Moderate and severe head trauma, traumatic brain injuries are associated with increased risk of AD. Head injury resulting in loss of consciousness or post traumatic amnesia lasting about 30mins is associated with twice the risk of developing AD; severe head injuries have about 4.5 fold risks. Mild cognitive impairment (MCI) has an established link with AD in which a person has problems with memory, language, and some essential cognitive ability severe enough to be noticeable to others and shown upon cognitive tests but not severe enough to interfere with the daily life. However there is no clear explanation on the fact that why some people with MCI develops dementia and in some cases it is not. The overall health of the heart and blood vessels shows a close linkage with the brain health since a brain is nourished by the rich network of blood vessels and a healthy heart pumps nutrient and oxygen rich blood to these vessels. Cardiovascular diseases, high blood pressure, hypertensions, type 2 diabetes, cholesterolemia, obesity, smoking habits, and physical inactivity potentially increases the risk of AD [6-9].
Alzheimer disease diagram, normal aged brain (left), Alzheimer brain (right)
Shrinkage of Brain tissue in Alzheimer disease
The human brain consists of 100 millions of neurons connected to each other through synapses forming communication network; each cells entitled to perform their own duties relating to memory, thinking, smell, taste, emotions etc. In case of AD these brain cells can’t perform their duties. Patho physiology of Alzheimer disease being complex and multi factorial shows important pathological changes in brain like accumulation of amyloid cerebral plaques and neurofibrillary tangles of abnormal insoluble ‘tau’ protein (Fig.6,8,9). AD is also considered a ‘tauopathy’ due to abnormal aggregation of the tau protein. Every neuron has a cytoskeleton, an internal support structure partly made up of structures called microtubules. These microtubules act like tracks, guiding nutrients and molecules from the body of the cell to the ends of the axon and back. A protein called tau stabilizes the microtubules when phosphorylated, and is therefore called a microtubule-associated protein. In AD, tau undergoes chemical changes, becoming hyperphosphorylated; it then begins to pair with other threads, creating neurofibrillary tangles and disintegrating the neuron\'s transport system [10,11].
Normal homeostasis of Alzheimer Disease
Normal Neuron (left), Neurofibrillary tangles, Amyloid plaques in Alzheimer (right)
As per the amyloid hypothesis, the neuropathologic hallmarks of AD are neuritic plaques and neurofibrillary tangles, consisting of hyper-phosphorylated microtubule-associated protein called ‘tau’ and extracellular amyloid plaques. The main component of amyloid plaques in AD is amyloid β (Aβ) peptide (38–43 amino acids) which is a proteolytic by-product from the amyloid precursor protein (APP) generated by the sequential β-secretase and γ-secretase cleavage (Fig.7). Research data have been shown that oligomeric Aβ species (smallest of which are dimers) isolated from AD brains are the most synaptotoxic forms. Aggregated amyloid fibrils, which are believed to be the toxic form of the protein disrupts the cell\'s calcium ion homeostasis, induces programmed cell death or apoptosis (Fig.7). It is also known that Aβ selectively builds up in the mitochondria in the cells of Alzheimer\'s-affected brains, and it also inhibits certain enzyme functions and the utilization of glucose by neurons [3,11-13].
Enzyme action on APP (Amyloid precursor protein) and its fragmentation
The brain of a Alzheimer patient shows marked histo-pathophysiological changes like, widened sulci and shrinkage of the gyri (Fig.10). In the great majority of cases, every part of the cerebral cortex is involved; however, the occipital pole is often relatively spared. The cortical ribbon may be thinned and ventricular dilatation apparent, especially in the temporal horn, due to atrophy of the amygdala and hippocampus. Microscopically, there is significant loss of neurons, in addition to shrinkage of large cortical neurons, synapses, in association with shrinkage of the dendritic arbor of large neurons, is thought to be the critical pathological substrate (Fig.4). Neurofibrillary tangles are the other characteristic neurohistopathologic hallmarks seen in AD. These tangles found inside the neurons, concentrated in vulnerable neural systems and composed of paired helical filaments of hyperphosphorylated micro-tubule-associated tau protein that may cause disruption of normal cytoskeletal architecture with subsequent neuronal cell death. Other pathological alterations commonly seen in the brains of AD patients include neuropil threads, granulovacuolar degeneration, and amyloid angiopathy. Amyloid angiopathy is a distinct vascular lesion found in many AD brains, consisting of amyloid deposition in the walls of small-to medium-sized cortical and leptomeningeal arteries. As a result of the deposits, the involved vessels may become compromised with resultant hemorrhage [14-17].
Inflammatory processes and cytokines play a controversial role in the pathology of Alzheimer\'s disease. Inflammation is a general marker of tissue damage in any disease, and may be either secondary to tissue damage in AD or a marker of an immunological response. Some studies have demonstrated the presence of activated microglia, a marker of the brain’s immune response. Alterations in the distribution of different neurotrophic factors and in the expression of their receptors such as the brain derived neurotrophic factor (BDNF) have been found in AD. Microglia have been shown to be significantly activated in AD brains and localized at sites of amyloid deposition. Early activation of microglia in early AD pathogenesis has been shown to be beneficial in scavenging and clearing toxic Aβ from the brain. Peri vascular macrophages like CD163 (hemoglobin-haptoglobin scavenger receptor) and CD206 (mannose receptor) are antigen-presenting phagocytic cells located in outer aspects of blood vessels within the brain, have shown to respond to CNS inflammation. Results of clinical trials have shown that, blood-derived macrophages from AD patients were shown to be less effective at phagocytosing Aβ compared with cells derived from non-demented control patients. Microglial and peri vascular macrophages may play role in clearing Aβ from the brain and in enhancing AD-related inflammation [18-20].
Neuro-fibrillary tangle with hyperphosphorylated Tau Protein(high resolution)
Changes in Tau protein & disintegration of microtubules in brain cells
Histopathologic image of senile plaques in Alzheimer Brain
Vascular dysfunction has a critical role in AD. Results of epidemiological and pathological studies have demonstrated positive links between cerebro vascular disorders and AD. For example a person with severe atherosclerosis is at a threefold increased risk of developing AD or vascular dementia. Due to reduced cerebral blood flow in AD there are abnormal cholinergic innervations of intra cerebral blood vessels leading to brain hypo perfusion. Results of recent investigations have shown that, the upregulation of two transcription factors myocardin (MYOCD) and serum response factor (SRF) in AD lead to arterial hypercontractility potentiating reduced cerebral blood flow. Other vascular anatomical defects observed in AD include atrophy and irregularities of arterioles and capillaries, increase in collagen IV, heparin sulfate proteoglycans and laminin deposition in the basement membrane, disruption of the basement membrane, reduced total micro vascular density, occasional swelling of astrocytic endfeets, and extensive degeneration of the endothelium during the disease progression [21-24].
Decreased cerebral blood flow (CBF) has a negative impact on the protein synthesis necessary for memory and learning, and may eventually lead to neuritic injury and neuronal death. Moreover due to cerebral hypo perfusion amyloid β-peptide (Aβ) clearance across the blood–brain barrier (BBB) will be impaired leading to accumulation of Aβ on cerebral blood vessels and brain parenchyma causing cerebral amyloid angiopathy (CAA), which is associated with cognitive decline and is another significant factor in the pathogenesis of AD. CAA can severely disrupt the integrity of the blood vessel wall resulting in micro or macro intra cerebral bleedings that exacerbates neurodegenerative process and inflammatory response and may lead to hemorrhagic stroke. Cerebral amyloid angiopathy (CAA) with Aβ deposits in the vascular smooth muscle cell layer is a major pathological threat to the neurovascular unit in AD [13,17,20,21].
Research evidences have suggested that imbalances between Aβ production and clearance from the brain cause accumulation of Aβ in the wall of cerebral vessels and in the brains of AD individuals. Aβ that is produced both in the brain and periphery by a number of different cell types is transported across the BBB via receptor-mediated transcytosis; the key receptors being involved are: RAGE (Receptor for Advanced Glycation End products) that transports Aβ from the blood into the brain and LRP (low-density lipoprotein receptor related protein-1) that is the major cell surface Aβ clearance receptor that transports Aβ out of the brain across the BBB and promotes Aβ clearance on VSMC. Aβ is not only cleared from the brain interstitial fluid (ISF) as a soluble peptide, but can also be transported by its chaperone proteins in the ISF, such as apolipoprotein E (apoE), apolipoprotein J, and α2-macroglobulin. Apart from direct Aβ clearance into the blood, alternative perivascular route for the clearance of Aβ in the human brain also exists. The pulsation force of cerebral blood vessels has been proposed to drive an Aβ drainage route along the perivascular spaces. Vessel constriction or stiffening reduces the pulsatile blood flow which in turn reduces Aβ clearance along the perivascular spaces leading to increase in Aβ deposition in the arterial wall of AD patients [20-24].
ApoE is a reactive apolipoprotein that exists in 3 iso forms (apoE2, apoE3, and apoE4) in humans has a major function in the transport of lipids and cholesterol in our body. Individuals who carry at least one apoE4 allele have great chances to develop AD. ApoE, an Aβ chaperone protein is found to be associated with impaired transport of Aβ across the BBB. Free Aβ can be rapidly cleared from the brain mainly via LRP or RAGE receptor mediated transcytosis, but Aβ-ApoE complexes (mostly apoE4-Aβ complexes in contrast to apoE2-Aβ and apoE3-Aβ complexes) are cleared by the very low-density lipoprotein receptor at a much slower rate, causing Aβ retention in the brain. Transport of Aβ via the receptor for advanced glycation endproducts (RAGE) across the BBB provides a major source of Aβ that can deposit in the brain and can directly lead to neuroinflammation by activating nuclear factor-κB mediated secretion of pro-inflammatory cytokines, such as tumor necrosis factor-α and interleukin 6 that may reduce the BBB potency [13,17,24-29].
Cascade of events in Alzheimer Disease
From the genetic point of view it has been found that the distribution of cerebrovascular amyloid in AD varies with apoE genotype and specifically the increasing dose of apoE4 alleles has been associated with increased CAA. Understanding the cellular and molecular mechanism by which apoE genotype influences the pathogenicity of the disease process in AD individuals can act as important targets in developing new therapeutic interventions and diagnostic aids for AD.
Interactions of Aβ with human Vascular Smooth Muscle Cells has been found to significantly increase the activation of matrix metalloproteinase 2 (MMP2) via increasing the mRNA expression of membrane type 1 (MT1)-MMP, the primary MMP2 activator at the cell surface. MMP9 specifically has been found in postmortem AD tissue in significant amounts. Activated MMP9 can degrade basement membranes, extracellular matrix proteins and tight junction proteins subsequently damaging the integrity of the BBB and potentially leading to spontaneous cerebral hemorrhages. Similarly high levels of ROS in AD may damage proteins essentials for important neurovascular mechanisms. The breakdown of the BBB may in turn disrupt the normal transport of nutrients, vitamins and electrolytes across the BBB, which are essential for proper neuronal functioning. Therefore, therapies that reduce ROS, MMP2, and MMP9, or that block RAGE-Aβ interaction may offer potentially useful strategies to correct BBB dysfunction in AD [12,25,27-30].
Research data of epidemiological studies have shown controversial results as regards the association between APOE polymorphism and the rate of progression of cognitive decline in AD after onset. Some reports have suggested that homozygous APOE ε4 patients have more rapid cognitive and functional decline following clinical disease onset, but an MRI study on a large cognitively normal population showed rate of volume decrease of entorhinal cortex and hippocampus suggesting potential development. Thus though the role of APOE in the predisposition of AD is well established, still further studies are needed to understand the possible association of APOE with rate of AD progression. The cascade of events in Alzheimer disease is depicted in Fig.11.
Alzheimer\'s disease is usually diagnosed clinically from the patient history, collateral history from relatives, and clinical observations, based on the presence of characteristic neurological and neuropsychological features and the absence of alternative conditions. Advanced medical imaging technologies like computed tomography (CT) or magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT) or positron emission tomography (PET) can be used to study the cerebral histo pathophysiological conditions of Alzheimer\'s disease. The Alzheimer\'s Disease and Related Disorders Association (now known as the Alzheimer\'s Association) have set up certain criteria for AD diagnosis which points to eight cognitive domains that are most commonly impaired in AD—memory, language, perceptual skills, attention, constructive abilities, orientation, problem solving and functional abilities. The presence of such symptoms should be confirmed by neuropsychological testing for a clinical diagnosis of possible or probable AD. A histopathologic confirmation including a microscopic examination of brain tissue is required for a definitive diagnosis. In addition to histopathologic confirmation, definite AD requires the clinical finding of dementia as determined by the Mini-Mental State Examination (MMSE) or other standardized neuropsychological testing; the examination must demonstrate deficits in two or more areas of cognition, with progressive memory loss in the absence of delirium. Assessment of intellectual functioning including memory testing can further characterize the state of the disease. The diagnosis can be confirmed with very high accuracy post-mortem when brain material is available and can be examined histologically. Neuropsychological screening tests can help in the diagnosis of AD. In the tests, people are instructed to copy drawings similar to the one shown in the picture, remember words, read, and subtract serial numbers. Neuropsychological tests such as the mini-mental state examination (MMSE), are widely used to evaluate the cognitive impairments needed for diagnosis. More comprehensive test arrays are necessary for high reliability of results, particularly in the earliest stages of the disease. Neurological examination in early AD will usually provide normal results, except for obvious cognitive impairment, which may not differ from that resulting from other diseases processes, including other causes of dementia. Interviews of family members and informations from caregivers about the patient’s daily living abilities, the person’s mental function are very important in this regard. Psychological tests for depression are also employed, since depression can either be concurrent with AD, an early sign of cognitive impairment, or even the cause [3,4,22].
With the advancements in imaging technology, computed tomography (CT) and magnetic resonance imaging (MRI) can be used to study the cortical atrophy, disproportionate volume loss in the medial temporal lobe structures and also normal age related changes that may be present at the early onset of disease. Functional imaging studies like the positron emission tomography (PET) and single-photon emission computed tomography (SPECT) scans, can be used as a diagnostic tool, which demonstrate hypometabolism and hypoperfusion, respectively, in the temporal-parietal regions bilaterally; for neuro imaging to confirm a diagnosis of Alzheimer\'s in conjunction with evaluations involving mental status examination (Fig.12). In a person already having dementia, SPECT appears to be superior in differentiating Alzheimer\'s disease from other possible causes, compared with the usual attempts employing mental testing and medical history analysis. Amyloid burden imaging compounds are under development. A new technique known as PiB PET has been developed that uses carbon-11 PET scanning for directly and clearly imaging beta-amyloid deposits in vivo using a tracer that binds selectively to the A-beta deposits with high levels of accuracy in predicting which people with mild cognitive impairment will develop Alzheimer\'s disease within two years. Volumetric MRI can detect changes in the size of brain regions and measure the atropy in those regions in order to study the progress of AD. Amyloid imaging used in conjunction with other markers can serve as an important diagnostic tool [3,4].
PET scan in the brain of Alzheimer patient (loss of function in temporal lobe)
Results of routine laboratory tests on chemistry panels, blood counts, metabolic panels (e.g., TSH) spinal fluid analyses, and inflammatory markers are all found to be within normal limits in patients with AD. Electroencephalographic (EEG) recordings are usually normal or show diffuse slowing in later stages of the disease. However it has been found that in AD patients it have been found that the levels of glutamate, creatinine, myo-inositol, N-acetyl aspartate are decreased as compared to normal people. Both decrease in N-acetyl aspartate/Creatinine ratio and decrease in hippocampal glutamate may be an early indicator of AD. Monitoring the level of blood dehydroepiandrosterone (DHEA) variations in response to an oxidative stress could be a useful proxy test for AD since experimental research data have shown that the subjects with Mild Cognitive Impairment did not have a DHEA variation, while the healthy controls did [3,4,8].
Another important marker of the disease is the analysis of cerebrospinal fluid for amyloid beta or tau proteins, both total tau protein and phosphorylated tau181P protein concentrations which predicts the onset of AD with a sensitivity of 94-100%. When used in conjunction with existing neuro imaging techniques, doctors can identify people with significant memory loss who are already developing the disease. Spinal fluid tests are commercially available, unlike the latest neuro imaging technology.
The differential diagnosis for AD is extensive and includes a multitude of neurodegenerative diseases that are associated with the development of dementia including Pick\'s disease, Lewy body disease, and other diseases such as vascular dementia and Creutzfeldt-Jakob disease. Most of these entities can be differentiated from AD by the clinical history and a careful examination. However, the challenge lies to test new hypotheses and not just to continue descriptive studies using better tools, technologies, increased parameters in CSF analysis and routine lab testing’s, and more descriptions about the amount of amyloid in the brain [3,4].
Virtually there are no proven modalities for cure of Alzheimer’s disease; however there are treatment regimens that may improve symptoms and may even delay their progression in the early and middle stages of the disease, allowing patients to maintain certain daily functions for longer. Various country- or region-specific, evidence-based guidelines have been developed for the treatment of Alzheimer’s disease. These make recommendations that vary according to available resources, funding practices, and local practice. In general, however, the guidelines provide recommendations regarding psychiatric management, psychosocial treatments, and the treatment of specific target symptoms. There are relatively few diseases that have been successfully prevented or even controlled without an understanding of specific etiology of the disease. Apart from the first line and second line FDA recommended synthetic drugs of choice in treating AD, some of the preventive strategies proved to be beneficial in AD include treatment of hypertension, omega fatty acid supplementation, physical activity and cognitive engagement.
From the point of conventional approach, major six classes of drugs are included in the treatment of AD: Acetylcholinesterase inhibitors (AChE-I), N-methyl-D-aspartate (NMDA) receptor antagonists, monoamine oxidase (MAO) inhibitors, antioxidants, metal chelators, anti-inflammatory drugs. AChE inhibitors are the first line agents for the treatment of mild to moderate AD. FDA approved five prescription drugs to control the symptoms of AD include: Donepezil, Galantamine, Rivastigmine, Tacrine among the AChE inhibitors and Memantine coming under NMDA receptor antagonists. However tacrine have been withdrawn due to the hepato toxicity effects. AChE inhibitors are prescribed to treat symptoms relating to memory, thinking, language, judgment and other thought processes. Cholinesterase inhibitors primarily act by increasing the levels of acetylcholine, the chemical messenger involved in memory, judgment and other thought processes. In AD the cells producing or using ACh are destroyed and thus less amount of ACh is available to carry messages. ACh is produced from acetyl-CoA and choline by cholineacetyltransferase which is released into the synaptic cleft and hydrolyzed by the actions of AChE to choline and acetic acid. This choline is reutilized in ACh synthesis. In the early stages of AD, the activity of AChE is found to be increased in the neuritic plaques and neurofibrillary tangles that accelerate aggregations of beta-amyloid. AChE inhibitors reversibly bind and block the activity of the enzyme acetyl cholinesterase that degrades ACh. AChE inhibitors block the actions of AChE thereby facilitating ACh neurotransmission and reducing beta-amyloid burden [31-34].
Basing on the cholinergic theory, different classes of drugs have been developed to enhance cholinergic deficit in AD patients. Amongst them, AChE inhibitors block the activity of AChE enzyme to improve cognitive function, choline precursors like phosphatidylcholine improves the bioavailability of choline, ACh releasers enhance the release of ACh, M1 and M3 receptor agonists mimic ACh on postsynaptic end terminal receptors, M2 and M3 receptor antagonists regulate ACh release via negative feedback, nicotinic agonists which would enhance ACh release.
AChE inhibitors are mostly well tolerated by the patients; however common side effects include nausea, vomiting, loss of appetite, increased frequency of bowel movements etc. Tacrine, the first FDA approved AD-drug, which inhibits AChE reversibly in a non-competitive manner is no longer in use due to severe side effects (hepatotoxicity) and short biological half life. Donepezil hydrochloride is the second drug of choice approved by USFDA for treatment of mild to moderate AD. This drug is a centrally acting, reversible and non-competitive AChE inhibitor having an N-benzylpiperidine and an indanone moiety which shows longer and more selective action. However it also suffers from the side effects of GI disturbances, nausea, vomiting, headache etc [31,33].
Donepezil hydrochloride
Galantamine reversibly inhibits AChE in a competitive manner and also acts on nicotinic acetylcholine receptors, beneficial for cognitive and non-cognitive AD symptoms. Results of clinical trials have reported this drug to be 50 times more potent against human AChE than butyrylcholinesterase at therapeutic doses. With escalations in drug doses some of the notable adverse effects include vomiting, nausea, diarrhoea etc. Rivastigmine is a reversible carbamate AChE inhibitor that interacts preferentially with acetylcholinesterase G1 with high brain selectivity; this drug has been approved in at least 40 countries around the world. Rivastigmine has the ability to inhibit the activity of butyrylcholinesterase. It binds to both the esteratic and ionic locations of AChE but dissociates at a much slower rate than AChE. Metrifonate, a precursor to the active pseudo irreversible AChE inhibitor DDVP (2,2-dichlorovinyl dimethyl phosphate) rapidly enters the brain with a longer plasma half life than donepezil but shows side effects of diarrhea and muscular cramps and hence could not achieve the market due to muscular weakness. There are certain AChE inhibitors of natural origin finding its use in AD. Physostigmine, a parasympathomimetic plant alkaloid isolated from the seeds of Physostigma venenosum have the ability to cross the BBB, having role in cholinergic transmission, can stimulate indirectly both nicotinic and muscarinic receptors. However physostigmine also inhibits another enzyme butyrylcholinesterase which has a role in AD and some of the adverse effects of this drug like nausea, vomiting, headache, diarrhea are attributed to its inhibitory actions on butyrylcholinesterase. Despite of the advantage to cross the BBB, the short half life, narrow margin of therapeutic index has restricted its potentiality. Galanthamine is an alkaloid isolated from Galanthus nivalis with competitive reversible AChE inhibitory activity. Galanthamine shows dual mechanism of action, AChE inhibition and allosteric modulation of nicotinic acetyl choline receptors. This drug has 10 fold selectivity for AChE than butyrylcholinesterase. Alpha-7 nicotinic acetylcholine receptors have a role in beta-amyloid mediated neurotoxiciy and since galanthamine can modulate nicotinic acetylcholine receptors it is suggested to prevent beta-amyloid mediated neurotoxicity. Huperzine A, an alkaloid drug isolated from club moss (Huperzia serrata) is claimed to show neuroprotective properties with significant improvements in cognitive function and results of clinical trials have shown this drug to be free from unexpected toxicities. This drug has attracted the attention of the scientists due to its strong AChE activities; (-)-huperzine A, a natural isomer have shown strongest dose dependent inhibitory activity against AChE, in comparison to commercially available synthetic drugs like donepezil, tacrine etc [31-33].
Memantine is an uncompetitive low-to-moderate affinity N-methyl-D-aspartate (NMDA) receptor antagonist that regulates glutamate activity. Glutamate plays an essential role in learning and memory by triggering NMDA receptors to let a controlled amount of calcium into the nerve cell. This calcium creates the chemical environment required for information storage. Excess glutamate on the other hand, over stimulates NMDA receptors so that they allow too much calcium into nerve cells leading to disruption and death of these cells. Memantine protects cells against excess glutamate by partially blocking NMDA receptors. It’s a recently FDA approved NMDA antagonist for the treatment of cognition in moderate to severe Alzheimer’s disease, having a half life period between 3-7 h and free from harsh adverse side effects. Memantine can be administered with AChE inhibitors. However FDA did not approve Memantine for mild AD. Results of clinical trials have shown small but statistically significant improvements in mental functions and ability to perform daily activities in AD patients [34,35].
AChE inhibitors (a) Tacrine (b) Donepezil (c) Galantamine (d) Rivastigmine (e) Metrifonate (f) Huperzine
Memantine
Rivastigmine
Galanthamine
Several metal species like iron, zinc, copper, aluminum are reported to induce beta amyloid aggregation and neurotoxicity in the brain of AD patients; results of structural evidences showing interrelations between aluminum and Abeta, presence of iron and zinc in abnormal high concentrations in AD patients have triggered the idea of using metal chelators as therapeutic targets in the treatment of AD. Desferrioxamine (DFO) and Clioquinol are clinically proven metal chelators used to treat AD patients. DFO chelates with metal ions or aluminium and reduces its neocortical concentrations thereby delaying the progression of dementia associated with AD and shows behavioral improvements. However the proper mechanism of action is not yet revealed. Transition metals like copper and zinc are found to be in high concentrations in the neo-cortical regions of the AD patients and these metals are mostly aggregated in the neurotic plaques potentiating beta amyloid aggregation and neurotoxicity. Clioquinol chelates with these metals and reduces the beta amyloid aggregation in the brain, thus finding use as a therapeutic target in treating Alzheimer [35].
(a) Desferrioxamine (b) Ferrioxamine B (c) Clioquinol (d) Clioquinol Zn complex (e) Clioquinol Cu complex
From the pathology of Alzheimer it is clear that several neurotransmitter systems, especially those regulating dopamine, serotonin, acetylcholine has a role in it. With the dysfunction of the dopaminergic system, there is increase in activity of type B monoamine oxidase, the enzyme responsible for degradation of dopamine. The increase in monoamine oxidase level is prominent in the brain platelets contributing to the severity of dementia. The drug Selegiline reversibly inhibits MAO-B; moreover it has a potent anti oxidative effect over the neurons of the brain and also protect against glutamate-receptor-mediated toxicity. Apart from MAO inhibition selegiline has a potent action in the recovery of damaged neurons involving a number of mechanisms like stimulation of neurite outgrowth, stimulation of gene expression in pre apoptotic neurons or stimulation of cytokine biosynthesis. Rasagiline, structurally similar to selegiline also shows neuro protective activities and is found to be ten times more active in inhibition of MAO-B. The propargylamine moiety in rasagiline is responsible for neuro protective activities. The drug Ladostigil, is the result of combination of active compounds from rasagiline (MAO-B inhibitor, neuroprotector) and rivastigmine (AChE inhibitor) thus finding application as a effective therapeutic agent in treating AD [33-35].
Monoamine oxidase inhibitors (a) Selegiline (b) Rasagiline
Oxidative damage to neurons has a significant role in the pathogenesis of AD; hence antioxidant therapy to prevent oxidative injury can be effective in preventing or retarding the progress of AD. Extracts from Ginko biloba named as Egb761 have been found to show cognitive improvement in AD patients and in those with multi-infarct dementia. Similarly Melatonin is found to have antiamyloidogenic activities and is found to reduce neuronal damage caused by reactive oxygen species in AD patients. Antioxidant therapy with vitamin E though reported in some cases but it does not improve cognitive impairment and its therapeutic use has not been established. Clinical trials with Idebenone, a co-enzyme Q10 analog have been found to attenuate Abeta-induced neurotoxicity and cognitive impairments. Dehydroevodiamine hydrochloride (DHED), a compound extracted from Evodia rutaecarpa showed AChE inhibitory activities, DHED protects neurons against hydrogen peroxide and glutamate. Moreover DHED decreases reactive oxygen species production and cell death induced by Abeta and carboxyterminal peptides of amyloid precursor proteins, thus improving cognitive impairments in AD. Metalloporphyrin antioxidants have been found to delay neuronal death resulting from increased mitochondrial oxidative stress; Mn-salen complexes have been found to be efficacious against oxidative stress [35].
Antioxidants: (a)alpha tocopherol (b) Melatonin (c) Manganese (ш) beta-octabromo-meso tetrakis (4-carboxy phenyl) porphyrin (d) Idebenone (e) Dehydroevodiamine (f) Mn-salen
In AD, neuronal destruction is due to inflammation around Abeta plaques. Drugs under the NSAID groups have anti-inflammatory actions, and found to inhibit cyclooxygenase-1 and cyclooxygenase-2 which are responsible for the oxidation of arachidonic acids to prostaglandins; however due to adverse effects of some NSAIDs on cardiovascular systems, these group of drugs have not found routine use in AD treatment.
NSAIDs (a) Ibuprofen (b) Aspirin (c) Naproxen (d) Flubiprofen
Polyunsaturated fatty acids or PUFA have significant biological roles in cellular structure and function. PUFA are the key components of phospholipids, comprising cellular and intracellular membranes. They govern the growth and vitality through oxidation (metabolism of food to produce energy required for cellular processes), chemical activities and transportation. In addition to being the structural materials for bio-membranes, PUFA are required for generating and propagating electrical impulses; synthesis of eicosanoids, important signaling hormones with numerous complex functions. Amongst its wide range of actions include anti-inflammatory, anti-thrombotic and vasodilatory properties, balancing and counteracting pro-inflammatory, vasoconstrictor actions of eicosanoids; the cardiovascular benefits of n-3 PUFA are largely attributed to these eicosanoid properties, and at the same time having significant roles in brain function. Polyunsaturated fatty acids like alpha linoleic acids (ALA), linolenic acids (LA), eicosapentaenoic acids (EPA) or docosahexaenoic acids (DHA) are not synthesized in the body and hence must be supplied in the diet [36].
Lipids constitute approximately sixty percent of the dry weight of the brain. DHA and Arachidonic acids (AA) are the most highly concentrated PUFAs present in neural phospholipids, including sub cellular membranes. DHA is particularly concentrated at neural synapses, retina, brain and nervous system. Though there is a predominance of omega-6 fatty acids in circulation, in contrast to omega-3 fatty acids, however DHA predominates in these vital structures. The amount of DHA levels in the neural phospholipids depend on the amount of dietary intake rich in omega-3 fatty acids. Clinical studies have shown that insufficient omega-3 PUFA during early neural development shows decreased DHA content in the brain.
The n-3 PUFAs have significant biological mechanisms in brain function. Neurotransmitters such as dopamine and serotonin have a role in mental illness, research data have focused on associations between PUFA and central nervous system activity. Levels of n-3 PUFA have been associated with monoaminergic neurotransmitter levels. There are indications that PUFA are involved in the synthesis and activities of brain peptides, which are involved in modulating the activities of neurotransmitters. Evidence points to the role of eicosanoids in healthy brain functioning, and phospholipid membranes in neural cell signaling. Results of animal studies have shown that, n-3 deficiency is found to reduce phosphatidylserine (PS) levels in the brain, which is thought to play an important function in neural signaling activities. In alcoholics, DHA deficiency has predicted reduced 5-hydroxyindoleacetic acid (5-HIAA) concentrations in cerebrospinal fluid, an indicator of low serotonin turnover rate in the frontal cortex. Studies have further indicated that n-3 PUFA may affect receptor properties or activation of signal transduction by receptors. Electrical impulse conduction is dependent on the exchange of ions through the cell membrane, which relies on the fluidity and physiological structure of cell membranes. Furthermore, n-3 PUFA are also thought to influence gene expression of a range of enzymes required for important neural functions including synaptic transduction, ion channel formation, energy metabolism and formulation of proteins vital for brain development and function. Regular delivery of oxygen and nutrients via the blood is also vital for optimal brain function, and psychopathology is associated with both reduced cerebral blood flow and transportation of glucose, the brain’s primary energy source, to brain regions as required. In this regard, n-3 PUFA are associated with production of nitric oxide, as well as anti-inflammatory and vasodilatory eicosanoids (notably PGI2), and are known to assist in endothelial-dependent vasodilatation. They have also been associated with substantially increased transport of glucose across the blood-brain barrier. Therefore, it is also possible that their primary influence on brain function includes improved cerebral blood flow and blood-brain barrier integrity. This idea is supported by the fact that there’s a high co-morbidity between cardiovascular disease and psychopathology, having a common underlying vascular pathology which can be mediated by lifestyle factors such as suboptimal levels of n-3 PUFA [36].
The mechanisms by which ω-3 fatty acids could interfere in AD patho physiologic features are not clear, but since anti-inflammatory effects are an important property of these fish oils rich in PUFA, they are applicable for AD also. Epidemiologic evidences have shown that administration of ω-3 fatty acid in patients with mild to moderate AD did not delay the rate of cognitive decline according to the MMSE or the cognitive portion of the Alzheimer Disease Assessment Scale but, positive effects were observed in a small group of patients with very mild AD. Increased intake of the ω-3 polyunsaturated fatty acids (primarily eicosapentaenoic acid (EPA), 20:5ω-3, and docosahexaenoic acid (DHA), 22:6ω-3) may be beneficial in reducing risk for AD. Increased fish consumption and diets supplemented with omega-3 fatty acids are found to exhibit a protective effect, cognitive improvement and enhancement of learning abilities. Animal studies on transgenic mouse model of AD with DHA-enriched diets significantly reduced total β-amyloid by 70% when compared with diets low in DHA or control chow diets [ext-link ext-link-type="bibr" rid="REF-NOC60062-9 REF-NOC60062-10"/].
However these findings cannot serve as a basis for general recommendations for treatment of AD with dietary DHA-rich fish oil preparations. Rather, larger cohort’s studies in patients with mild cognitive impairment, including those at risk for AD are needed to further explore the potentiality of the ω-3 fatty acids in halting initial progression of the disease [36].
Though a number of FDA approved drugs are currently available for the treatment of Alzheimer but there are no such effective treatments to stop the insidious nerve cell death process once the disease begins. Available drugs can manage and ease some of the symptoms of the disease but the progression of the disease can in no way be slowed down by these treatments. In AD patients there is very less production of neurotransmitter acetylcholine due to the progressive damage of the cells producing acetylcholine. Most of the FDA approved drugs aim to prevent the breakdown of acetylcholine by inhibiting the enzyme acetyl cholinesterase. But in AD due to rapid destruction of nerve cells, the acetylcholine produced even though protected from further breakdown but the amount produced is significantly insufficient to transmit messages between the brain cells. This fact necessitates further new drug development.
In contrast to traditional drug discovery, “Rational Drug Design’’ has been found to be a more deterministic approach where the first necessary step is the identification of the molecular target critical to the disease process and then determine the molecular structure of the target molecule. In-silico drug design approach makes use of Computer Assisted Drug Design (CADD) tools to find a ligand (putative drug) that will interact with a receptor which represents the ‘target site’. A ligand can bind to the receptor either by hydrophobic, electrostatic or hydrogen bonding interactions and solvation energies of the ligand and receptor sites are the important facts to be considered in this case.
The basics behind the pathology of AD is the presence of neuritic plaques containing amyloid-β-peptide (Aβ) and intra neuronal accumulation of tubule associated ‘tau’ protein. In order to target therapeutic strategies basing on molecular mechanisms for AD, new drug entities can be developed that will act directly on the Aβ or the amyloid precursor protein (APP) processing which may include vaccination with Aβ peptide, Aβ passive immunization. However clinical trials with a vaccine made of synthetic Aβ 1-42 showed the lateral development of encephalitis and hence the trial was put on hold though the concept exists. Passive immunization can be obtained by monoclonal antibodies against Aβ. New anti-amyloid agents to prevent fibrillizations can be designed by detailed characterizations of the proto fibrils and fibril formations. Another lucrative approach is to target the APP processing where the three major enzymes are to be targeted: alpha secretase, beta secretase and gamma secretase, the basic aim is to increase the alpha cleavage or to decrease the beta and gamma secretase activities. Nerve growth factors and neurotrophines can also act as important therapeutic targets. Growth factor gene therapy (though under clinical trial) where patient’s fibroblasts transfected with NFG and transplanted to brain are expected to be effective in case of severe AD [37].
In in -silico drug design approach, computational docking techniques can be used to develop an effective drug to prevent the progression of Alzheimer disease. Here the ‘TARGET’ is the amyloid precursor protein (APP) and the ‘LEAD COMPOUND’ is the protease enzyme. By the aid of database search tools like FASTA, BLAST in Swissport, proteins having protease activity for b-APP can be identified. Next step is to identify the protease enzyme that cleaves the b-APP so as to prevent the formation of beta-amyloid peptide. Structural informations on b-APP is available from PDB (Protein Data Bank) with ID 1RW6. Soft wares like PASS, CASTp provides information about the active site for b-APP. Enzyme modeling can be done using packages like Swiss Model, Modeller etc. Specific interactions of these lead compounds with the active site of b-APP can be studied by docking programs like DOCK, AUTODOCK etc. The most effective protease enzyme with minimum energy conformation can be identified by the above procedure which will act as the potential drug in treating Alzheimer. Use of computational docking techniques help to explore a large number of compounds, study the binding characteristics of ‘hits’ and is found to be effective in reducing the time and monetary expenditure as associated with traditional drug development techniques [38].
Virtually at this point of time there is no cure for Alzheimer. But apart from therapeutic interventions, attempts can be done to manage the disease and treat the symptoms by the care givers in a non-pharmacologic manner. Along with medications, physical exercise, social involvement as well as proper nutrition are essential in treating the symptoms of AD. The goal of non-pharmacologic treatment in AD though sounds simple but clinically remains a challenge where the care giver has a vital role to play; first thing is to provide a calm structured environment where the comfort, dignity of the afflicted person is maintained and the patient remains functioning as long as possible [39-41]. For AD patients the environment should be so arranged that maximize use of cognitive capacities of AD patients that are intact and compensate for those cognitive capacities that decline. Treatment in a non-pharmacologic manner aims to improve the quality of life to treat the disease symptoms. It is not a simple task for a care giver to increase functional independence, reduce the need for psychoactive medications, prolong life, reduce the need for restraints, reduce acute hospital admissions, reduce depression and improve morale. Alzheimer begins in the medial temporal lobe and spreads to other parts of the brain slowly destroying parietal, temporal and frontal lobes, cingulated cortex, hippocampus, amygdale, damaging the tempero-parieto-occipital association cortex leading to memory dysfunction, emotional disturbances, personality changes, visual, language and movement disorders. Due to damages in the frontal lobes AD patients will have difficulty in performing daily tasks; with the gradual progression of the disease hallucinations, delusions, paranoia, agitation, panic and denial are seen among the afflicted. Among the non-pharmacologic treatment domains include: properly mapped physical environment that removes fear and promotes safety, induce a sense of positive attitude or emotion among the afflicted persons by the care giver while helping in daily activities by helping them to perform the task but not to do the total task for them and make them even more dependent; change negative emotions and promote feelings of purpose and accomplishment. While treating AD patients in non-pharmacologic manner one of the major corner stone is how we understand the afflicted person and help him to understand himself [42-44]. The care giver must change his/her behavior & environment in order to change the behavior of the patient. A person in middle stage of AD should never be attempted to bring back to the realistic world but reduce his fear in all possible stages and help him to move into his sense of the world. Due to sensory impairment and lack of receptive and expressive language abilities non-verbal perceptual inputs which replace words like familiar music, known food smell, and known touch may be used and afflicted can be communicated with a look, tone or a hug to induce a feeling of care and safety. In case of negative behavior and aggression the triggering agent should be identified and eliminated. The ultimate outcome of such a treatment approach is to slow the rate of disease progression, delay institutionalization, improve the quality of life and reduce the need for medication [39]. Below in fig.22 a specially designed room is shown for sensory integration therapy.
Specially designed room for sensory integration therapy (Snoezelen); an emotion oriented psychosocial intervention for people with dementia
There is an increasing emergency in finding a prevention or treatment for AD and dementia because of the aging of the populations and realizing the severity and complications associated with this deadly disease. Fortunately, AD and dementia research is now at a progressing stage. Availability of improved medical imaging technologies like CT scan, MRI, PET, use of biomarkers helps in early diagnosis of the disease, its progression and severity. Furthermore, pharmacological and non-pharmacological therapies could be directly tested both to prevent and delay the progression of amyloid in the brain and effects on brain morphology and cognitive decline. Pharmacological therapies that could delay the onset of dementia for several years could result in a substantial reduction in the prevalence of AD because the patients will die of another cause before they develop AD. A second and far more important approach will be the application of these new technologies to understand the etiology of AD. The identification of specific etiological factors is much more likely in the long term to have a major impact on the incidence, prevalence, and disability because of AD and dementia. Proper understanding the etiology of the disease is essential to develop hypothetical treatment approaches which can be further clinically established. Basing on in-silico drug design approaches it is essential to understand the molecular mechanisms of APP processing, role of folate and homocysteine in neuronal homeostasis. Main target should be to develop novel therapeutic agents via cost effective, eco-friendly methodologies. Along with specific drug therapy, lifestyle interventions and environmental variables are also to be targeted to reduce the incidence of AD. However in case of new drug research in Alzheimer, ability to utilize the technologies, clinical skills and financial resources to support research studies are of vital importance.
The alkali and alkaline earth metal cations have inert gas electronic structures and are not expected to show any stereochemical requirements in their complex formation as do transition metal cations. They may be considered spherical even in the complex state. Their complexation is thus treated as recognition of spherical cations by organic ligands [1]. Depending upon the nature of the organic ligand and the anion, the metal ions can be separated as solvated ions, solvent separate, loose and tight ion pairs.
Alkali and alkaline earth metal ions form a large number of solid complexes with podands [2, 3, 4, 5, 6]. The podands are inherently flexible because the two ends of the molecule are not tied simultaneously. Polypodal ligands are acyclic multidentate ligands containing more than three arms. They form an unlimited family of structures which finally give rise to dendrimers. A predominant 1:1 complexation has also been observed in alkali and alkaline earth metal complexes of the tetra- and pentapodands. The stability constants of the terapodands are generally lower than those of the corresponding tripodands because of more severe steric hindrance to complexation [7]. Vögtle and coworkers have indicated that the ligands resembling tetrapodands are capable of forming 1:1 complexes with s-block metal ions [8, 9].
The s-block elements present a usual challenge in the molecular modeling, because the metal-ligand interactions in both cases are principally electrostatic. The types of alkali and alkaline earth metal complexes subjected to molecular modeling can be divided into five categories: crown ethers [10, 11, 12, 13, 14, 15, 16], cryptands [17, 18], spherands [19, 20], podands and other biologically important ligands, such as ionophores and cyclic antibiotics [21, 22, 23, 24] . The present work has been undertaken with the aim to computationally characterize the structure and nature of complexes of s-block metal ions with the tetrapodands THEEN and THPEN. Recently the computational studies of these tetrapodal ligands with Cu(II), Ag(I) and La(III) have been reported. Recently, synthesis, crystal structure and biological properties of [Co(edtp)Cl]·NO3·H2O complex was also determined, where edtp is N,N,N′,N′-Tetrakis(2-hydroxypropyl) ethylenediamine in which Co2+ ion is coordinated by the N,N′,O,O′,O″-pentadentate edtp ligand and a chloride to generate a distorted CoClN2O3 octahedron [25, 26, 27, 28].
From the last 3 decades density functional theory has been the dominant method for the quantum mechanical simulation of periodic systems. In recent years it has also been adopted by quantum chemists and is now very widely used for the simulation of energy surfaces in molecules. The quantum-chemical calculations (DFT calculations) giving molecular geometries of minimum energies, molecular orbitals (HOMO-LUMO), 13C-NMR and vibrational spectra were performed using the Gaussian 09 [29]. Molecular orbitals were visualized using “Gauss view”. The method used was Becke’s three-parameter hybrid-exchange functional, the nonlocal correlation provided by the Lee, Yang and Parr expression, and the Vosko, Wilk, and Nuair 1980 local correlation functional (III) (B3LYP) [30, 31]. The 6-31 g + (d,p) basis set was used for C, N and O. The LANL2DZ basis set [32] and pseudopotentials of Hay and Wadt were used for Ca, Sr, Ba and Na metal atoms [33, 34]. DFT calculations were performed in the gaseous phase and the input coordinates were obtained from and then compared with crystal structure data of already reported complexes: [Ca(THEEN)(PIC)](PIC),[Ca(THPEN)(H2O)2](PIC)2, Ba(THPEN)(PIC)2, [Na(THPEN)]2(PIC)2, [Sr(THPEN)(H2O)2]2(DNP)4 and [Ba(THPEN)(H2O)2]2(DNP)4 (where DNP is 3,5-dinitrophenolate) [35]. The structural parameters were adjusted until an optimal agreement between calculated and experimental structure obtained throughout the entire range of available structures. HOMO-LUMO analyses and spectroscopic calculations were performed on the optimized geometries of the title complexes (1–6) using B3LYP/6-31 g + (d,p)/LANL2DZ level of theory.
Complexes (1–6) were successfully modeled by using the input coordinates of crystal data. Tables 1 and 2 represent comparison of calculated and experimental M-Ligand bond lengths (Å) of complexes (1–3) and (4–6), respectively. The picrates and dinitrophenolates that are excluded from the primary coordination spheres of metal atoms in the crystallographic determinations, are not optimized in the computed structures. Tables 3 and 4 represent comparison of calculated and experimental torsion angles of ligand in complexes (1–3) and (4–6) respectively.
Complex 1 (M = Ca) | Complex 2 (M = Ca) | Complex 3 (M = Ba) | |||||||
---|---|---|---|---|---|---|---|---|---|
Theo. | Exp. | Dev. | Theo. | Exp. | Dev. | Theo. | Exp. | Dev. | |
M-O1 | 2.450 | 2.410 | 0.040 | 2.389 | 2.341 | 0.048 | 2.720 | 2.722 | −0.002 |
M-O2 | 2.450 | 2.380 | 0.070 | 2.495 | 2.498 | −0.003 | 2.807 | 2.812 | −0.006 |
M-O3 | 2.410 | 2.480 | 0.070 | 2.753 | 2.753 | 0.000 | |||
M-O4 | 2.410 | 2.370 | 0.040 | 2.812 | 2.816 | −0.004 | |||
M-O5 | 2.681 | 2.687 | −0.006 | ||||||
M-O6 | 3.127 | 3.135 | −0.008 | ||||||
M-O12 | 2.310 | 2.30 | 0.01 | 2.728 | 2.735 | −0.007 | |||
M-O13 | 2.470 | 2.73 | 0.26 | ||||||
M-O18 | 2.977 | 2.990 | −0.013 | ||||||
M-O1W | 2.440 | 2.442 | −0.002 | ||||||
M-O2W | |||||||||
M-N1 | 2.824 | 2.591 | 0.233 | 2.601 | 2.603 | −0.002 | 3.038 | 3.042 | 0.004 |
M-N2 | 2.738 | 2.658 | 0.08 | 3.026 | 3.032 | −0.006 |
Comparison of experimental and calculated M-ligand bond lengths (Å) of complexes (1–3).
Complex 4 (M = Na) | Complex 5 (M = Sr) | Complex 6 (M = Ba) | |||||||
---|---|---|---|---|---|---|---|---|---|
Theo. | Exp. | Dev. | Theo. | Exp. | Dev. | Theo. | Exp. | Dev. | |
M-O1 | 2.412 | 2.416 | −0.004 | 2.617 | 2.628 | −0.011 | 2.736 | 2.743 | −0.007 |
M-O2 | 2.393 | 2.396 | −0.003 | 2.611 | 2.618 | −0.007 | 2.763 | 2.767 | −0.004 |
M-O3 | 2.505 | 2.508 | −0.003 | 2.506 | 2.516 | −0.010 | 2.756 | 2.762 | −0.006 |
M-O4 | 2.628 | 2.632 | −0.004 | 2.618 | 2.626 | −0.008 | 2.658 | 2.668 | −0.010 |
M-O1W | 2.701 | 2.711 | −0.010 | 2.880 | 2.884 | −0.004 | |||
M-O2W | 2.699 | 2.705 | −0.006 | 2.988 | 2.995 | −0.007 | |||
M-O2WA | 2.726 | 2.732 | −0.006 | ||||||
M-N1 | 2.835 | 2.842 | −0.007 | 3.009 | 3.008 | −0.001 | |||
M-N2 | 2.849 | 2.857 | −0.008 | 3.010 | 3.010 | 0.000 |
Comparison of experimental and calculated M-ligand bond lengths (Å) of complexes (4–6).
Name of the | Complex (1) | Complex (2) | Complex (3) | ||||||
---|---|---|---|---|---|---|---|---|---|
Atoms | Theo. | Exp. | Dev. | Theo. | Exp. | Dev. | Theo. | Exp. | Dev. |
O1-C1-C2-N1 | −55.1 | −55.05 | 0.05 | 57.9 | 58.0 | 0.1 | −32.3 | −32.4 | −0.1 |
C1-C2-N1-C5 | 165.1 | 165.1 | 0.0 | 82.8 | 82.7 | 0.1 | 161.9 | 162.0 | 0.1 |
C2-N1-C5-C6 | −159.0 | −159.0 | 0.0 | −165.5 | −165.5 | 0.0 | −157.6 | −157.8 | −0.2 |
N1-C5-C6-N2 | 65.4 | 65.3 | 0.1 | 60.4 | 60.5 | 0.1 | 65.9 | 66.1 | 0.2 |
C5-C6-N2-C8 | −159.1 | −159.0 | 0.1 | −159.3 | −159.4 | 0.1 | |||
C6-N2-C8-C7 | 89.1 | 89.1 | 0.0 | 163.6 | 163.7 | 0.1 | |||
N2-C8-C7-O3 | 60.9 | 60.9 | 0.0 | −34.1 | −34.2 | −0.1 | |||
O2-C3-C4-N1 | 36.5 | 36.7 | 0.2 | 55.5 | 55.6 | 0.1 | 46.8 | 46.9 | −0.1 |
C3-C4-N1-C5 | −121.6 | −121.7 | −0.1 | −161.0 | −161.0 | 0.0 | −132.6 | −132.7 | −0.1 |
C4-N1-C5-C6 | 77.2 | 77.2 | 0.0 | 72.6 | 72.6 | 0.0 | 83.7 | 83.8 | 0.1 |
C5-C6-N2-C10 | 79.4 | 79.4 | 0.0 | 79.0 | 79.1 | 0.1 | |||
C6-N2-C10-C9 | −151.8 | −151.8 | 0.0 | −134.9 | −134.9 | 0.0 | |||
N2-C10-C9-O4 | 61.3 | 61.4 | 0.1 | 52.1 | 52.2 | 0.1 |
Comparison of calculated and experimental torsion angles (°) of ligand in the complexes (1–3).
Name of the | Complex (4) | Complex (5) | Complex (6) | ||||||
---|---|---|---|---|---|---|---|---|---|
Atoms | Theo. | Exp. | Dev. | Theo. | Exp. | Dev. | Theo. | Exp. | Dev. |
Complex | −55.6 | −55.7 | −0.1 | 32.3 | 32.3 | 0.0 | −43.4 | −43.5 | 0.1 |
O1-C1-C2-N1 | 152.7 | 152.6 | 0.1 | −143.9 | −143.9 | 0.0 | 162.3 | 162.4 | 0.1 |
C1-C2-N1-C5 | −80.2 | −80.2 | 0.0 | 86.1 | 86.1 | 0.0 | −92.7 | −92.8 | 0.1 |
C2-N1-C5-C6 | −64.0 | −63.9 | −0.1 | 43.6 | 43.6 | 0.0 | −50.1 | −50.1 | 0.0 |
N1-C5-C6-N2 | 165.5 | 165.4 | 0.1 | −146.4 | −146.4 | 0.0 | 156.5 | 156.7 | 0.2 |
C5-C6-N2-C8 | −85.7 | −85.7 | 0.0 | 156 | 155.9 | 0.1 | −89.6 | −89.9 | 0.3 |
C6-N2-C8-C7 | −60.3 | −60.4 | −0.1 | −44.7 | −44.7 | 0.0 | −30.4 | −30.4 | 0.0 |
N2-C8-C7-O3 | −59.7 | −59.8 | −0.1 | −17.4 | −17.4 | 0.0 | 47.8 | 48.1 | 0.3 |
O2-C3-C4-N1 | −91.0 | −91.1 | −0.1 | 112.7 | 112.7 | 0.0 | −135.1 | −135.2 | 0.1 |
C3-C4-N1-C5 | 156.0 | 156.0 | 0.0 | −159.1 | −159.2 | 0.1 | 151.9 | 151.9 | 0.0 |
C4-N1-C5-C6 | −72.4 | −72.5 | −0.1 | 97.4 | 97.4 | 0.0 | −92.1 | −92.4 | 0.3 |
C5-C6-N2-C10 | 156.6 | 156.6 | 0.0 | −151.8 | −151.8 | 0.0 | 143.4 | 143.9 | 0.5 |
C6-N2-C10-C9 | −59.2 | −59.3 | −0.1 | 41.6 | 41.7 | 0.1 | 5.1 | 4.9 | 0.3 |
N2-C10-C9-O4 | −55.6 | −55.7 | −0.1 | 32.3 | 32.3 | 0.0 | −43.4 | −43.5 | 0.1 |
Comparison of experimental and calculated and torsion angles (°) of ligand in the complexes (4–6).
The coordination number of Ca(II) ion is eight with distorted cube geometry in the optimized geometry of cationic complex (1) (Figure 1). THEEN is interacting with Ca(II) ion through all the six potential donor atoms. The seventh and eighth coordination sites of Ca(II) are occupied by picrate anion through phenolic oxygen and one of the o-nitro oxygen. The observed and calculated positions of calcium and donor atoms are in agreement. A comparison of bond lengths and bond angles provided a maximum tolerance of 0.27 Å and 16.33°Å, respectively (Table 1 and Table S1; Figure S1a,b) of computed title complex (1) and crystallographically determined complex [Ca(THEEN)(PIC)](PIC). The torsion angles of the ligand THEEN in theoretically determined and experimental complex are also in well consistency with each other (Table 3). The HOMO-LUMO analysis has indicated that there is maximum distribution of HOMO over the carbon atoms and to a lesser extent on the oxygen of the coordinated picrate. LUMO is mainly distributed or concentrated on all the atoms of coordinated picrate except p-nitro group. Neither HOMO nor LUMO distribution is found either on calcium ion or on any ligand atom. The HOMO-LUMO gap (ΔE) is found to be 0.852 eV (Figure S1c).
(a) Optimized geometric structure of [Ca(THEEN)(PIC)]+ (1) (b) distorted cube geometry.
Ca(II) is eight coordinated in monomeric cationic complex with a distorted square-antiprismatic geometry in complex (2) as is observed in crystal structure of [Ca(THPEN)(H2O)2] (PIC)2. H2O (Figure 2). THPEN is acting as hexadentate ligand towards the metal ion. Two remaining sites around the metal ion are occupied by two water molecules. The observed and calculated positions of calcium and donor atoms are in agreement. All strain energy minimized structures reproduced the observed X-ray structures with almost no deviation in M-L bond length and torsion angle of the ligand (Table 3). The maximum tolerance of L-M-L bond angle is 15.8° (Tables 1 and Table S1, Figure S2a,b). Complex 2 is displaying the main distribution of HOMO as well as LUMO only on water molecules. There is slight distribution of HOMO and LUMO on hydroxyl oxygen of THPEN ligand also with HOMO-LUMO gap (HLG) of 0.419 eV (Figure S2c).
(a) Optimized geometric structure of [Ca(THPEN)(H2O)2]2+ (2) (b) distorted square-antiprismatic geometry.
Ba(II) is ten-coordinate in its monomeric complex (3) (Figure 3). The ligand THPEN coordinates through both its nitrogen atoms and all the four hydroxyl oxygen. The two picrate ions are also directly coordinated to Ba2+ ion through the phenolic oxygen and one oxygen of the o-nitro group. Since both the picrates are directly interacting with the cation, the complex is termed as tight ion-paired complex as is found in the crystallographically determined complex. The observed and calculated positions of barium and donor atoms are in agreement. There is negligible deviation found in bond length, bond angle (0.11°) and torsion angle of ligand THPEN for calculated title complex (3) and experimental Ba(THPEN)(PIC)2 (Tables 1 and 3 and S1, Figure S3a,b). An analysis of HOMO-LUMO has illustrated that HOMO is mainly distributed on the ligand THPEN with a small distribution on coordinated picrates. In contrast to this LUMO is mainly distributed on coordinated picrates with no distribution over the ligand or metal atom. The complex is showing HLG of 0.118 eV (Figure S3c).
(a) Optimized geometric structure of Ba(THPEN)(PIC)2 (3) (b) bicapped square-antiprismatic geometry.
Figure 4a shows the optimized structure of the cationic complex of sodium (4). This structure is centrosymmetric dimer. The coordination number around each Na+ ion is seven. Each THPEN ligand coordinates to Na(I) ion in a heptadenate fashion (Figure 4). In other words, one hydroxyl group of the THPEN ligand acts as a bridge between two Na+ ions. The geometry of the complex is distorted monocapped octahedron. The Na…Na non bridging distance is 3.429 Å. Almost no deviation has been observed in bond length (M-L), torsion angle of ligand THPEN and bond angles (L-M-L) of computed title complex (4) and crystallographically determined complex [Na(THPEN)]2(PIC)2 (Tables 2 and 4 and Table S1, Figures S4a,b). The HOMO-LUMO study has revealed that in the title complex (4) HOMO is mainly concentrated on bridged hydroxyl oxygens and sodium metal but to a smaller extent on the other coordinated hydroxyl oxygens and amine nitrogens. LUMO is mainly concentrated on bridged hydroxyl oxygens and to a smaller extent on other coordinated oxygen atoms. The HOMO-LUMO gap is 0.261 eV (Figure S4c).
(a) Optimized geometric structure of [Na(THPEN)]22+(4) (b) distorted monocapped octahedron geometry.
Sr(II) is nine-coordinated in its dimeric complex (5) (Figure 5). This cationic complex is having tricapped trigonal-prismatic geometry as is found in crystallographically determined complex [Sr(THPEN)(H2O)2]2(DNP)4. Each Sr2+ ion in the complex is coordinated by six potential donor sites of the ligand THPEN and four water molecules. Out of four water molecules, two are bridging and the third one is non-bridging. Sr…Sr non bridging distance is 4.346 Å indicating the existence of van der Waals contact. All strain energy minimized structures reproduced the observed X-ray structures to a maximum tolerance of 9.07° bond angle (Table 2 and Table S1, Figure S5a,b). Almost no deviation of M-L bond length and torsion angle of ligand THPEN has been observed for the title complex (5) and crystallographically determined complex (Tables 2 and 4). The HOMO-LUMO analysis has shown that the complex (5) is having maximum distribution of HOMO and LUMO on bridged coordinated water molecules and there is HLG of 0.0225 eV (Figure S5c).
(a) Optimized geometric structure of [Sr(THPEN)(H2O)2]2(DNP)4 (b) Trigonal- prismatic geometry.
Ba(II) is ten-coordinate in the cationic title complex (6) as is found in the crystallographic determined complex [Ba(THPEN)(H2O)2](DNP)4. The geometry around Ba(II) is bicapped cubic. Each Ba(II) in dimer is interacting with THPEN through all its six potential donor sites and four water molecules. The latter are bridging in nature. The existence of van der Waals contact between non-bridging Ba…Ba is indicated by their larger distance (4.196 Å). The observed and calculated positions of the metal and donor atoms are in agreement as almost negligible deviation of M-L bond length and torsion angle of THPEN. A deviation of 0.14° of bond angle L-M-L has been observed for complex (6) [Ba(THPEN)(H2O)2](DNP)4 (Tables 2 and 4 and Table S1; Figures S6a,b and S7). The region of distribution of HOMO and LUMO is only over two of the bridged water molecules in complex (6) with a very small HOMO-LUMO gap (ΔE = 0.0375 eV) indicating the soft nature of complex (Figure 6).
(a) Optimized geometric structure of [Ba(THPEN)(H2O)2]22+ (6) (b) Bicapped cubic geometry.
Smaller is the HUMO-LUMO gap (HLG) softer is the complex [36, 37]. The frontier orbitals HOMO and LUMO are very important parameters for chemical reaction and take part in chemical stability [38, 39, 40]. It is predicted from the HOMO-LUMO gaps that the title complexes are soft as is obvious from their smaller HUMO-LUMO energy gaps (HLG) relative to the similar reported complexes of copper, silver and lanthanoid [25, 26, 27] (Table 5). It has been observed in the present computational study that the dinitrophenolate complexes are softer than trinitrophenolate and among the latter, [Ca(THEEN)(PIC)]+ (1) is displaying least softness. It is pertinent to mention here that the complex (1) is having THEEN ligand whereas THPEN is ligand in rest of the complexes (2–6).
HLG (eV) | Reported complexes | HLG (eV) | Reported complexes | HLG (eV) | |
---|---|---|---|---|---|
[Ca(THEEN)(PIC)]+ (1) | 0.852 | [Cu(THEEN)(H2O)](PIC)2 | 3.537 | [La(THEEN)(PIC) (H2O)2] (PIC)2.2H2O | 3.428 |
[Ca(THPEN)(H2O)2]2+ (2) | 0.419 | [Cu(THPEN)](PIC)2.C3H8O | 3.467 | [La(TEAH3)(H2O)2] (PIC)3 | 3.673 |
Ba(THPEN)(PIC)2 (3) | 0.118 | [Cu(TEAH3)(PIC)](PIC).H2O | 3.619 | ||
[Na(THPEN)]22+ (4) | 0.261 | [Ag (THEEN)]2 (PIC)2 | 2.530 | ||
[Sr(THPEN)(H2O)2]22+ (5) | 0.0225 | [Ag (THPEN)]2 (PIC)2 | 2.640 | ||
[Ba(THPEN)(H2O)2]22+ (6) | 0.0375 | [Ag(TEAH3)2] (PIC) | 1.061 |
Nuclear magnetic resonance spectra (NMR) and infrared (IR) spectroscopy can be useful for studying the coordination of various ligating sites. The 13C-NMR spectra were predicted for complexes (1–6) using DFT/B3LYP/6-31G** method and the spectral data was compared with experimental data reported in literature [35]. The computed NMR spectral data is fairly in agreement with experimental data (Tables 6 and 7). Small deviations are due to the fact that H-bonding interactions or any type of lattice interactions are not modeled in theoretically computed structures. The terminal methyl groups in theoretically predicted complexes (2–5) are displaying quiet high upfield shifts relative to the experimentally obtained due to more free movements in the gaseous phase than in solution or solid phase.
Assignments (δ) | [Ca(THEEN)(PIC)]+ (1) | Ba(THPEN)(PIC)2 (3) | ||
---|---|---|---|---|
Theo. | Exp. | Theo. | Exp. | |
▬CH3 | * | * | 4.22 | 19.61 |
▬CH3 | 4.49 | 19.89 | ||
▬NCH2 | 52.31 | 55.03 | 51.73 | 55.34 |
▬NCH2 | 43.35 | 55.20 | ||
▬OCH2, ▬OCH | 59.03 | 57.47 | 50.75 | 63.00 |
▬ArCH | 113.63 | 124.33 | 117.85 | 124.36 |
p-ArCN | 134.75 | 123.60 | 122.06 | 123.68 |
o-ArCN | 140.68 | 140.78 | 140.98 | 140.78 |
▬ArCO | 161.57 | 160.20 | 150.21 | 160.20 |
Comparison of calculated and experimental 13C-NMR spectral data for complexes (1 and 3).
* Group absent.
Assignment (δ) | [Ca(THPEN)(H2O)2]2+ (2) | [Na(THPEN)]22+ (4) | [Sr(THPEN)(H2O)2]22+ (5) | [Ba(THPEN)(H2O)2]22+ (6) | ||||
---|---|---|---|---|---|---|---|---|
Theo. | Exp. | Theo. | Exp. | Theo. | Exp. | Theo. | Exp. | |
▬CH3 | 11.35 | 18.79 | 4.01 | 20.30 | 3.77 | 18.31 | 27.02 | 18.35 |
▬CH3 | 11.38 | 19.02 | 5.63 | 20.36 | 3.85 | 18.59 | 27.69 | 18.63 |
▬NCH2 | 39.60 | 50.99 | 43.05 | 50.42 | 43.60 | 48.31 | 61.69 | 59.80 |
▬NCH2 | 39.61 | 51.76 | 44.05 | 52.90 | 57.81 | 59.68 | 61.69 | 60.59 |
▬OCH | * | * | 50.73 | 55.73 | 41.85 | 60.62 | 60.37 | 60.66 |
▬OCH | 69.24 | 61.74 | 57.90 | 55.95 | 51.91 | 61.08 | 60.38 | 62.53 |
Comparison of calculated and experimental 13C-NMR spectral data for complexes (2, 4–6).
* Group absent.
The computed IR spectral peaks that appear in the range of 1370–600 cm−1 are fairly in agreement with the experimental data (Tables 8 and 9). The absorption peaks due to the presence of hydroxyl groups were observed only for complexes (1) and (6) in the computed IR spectra. It is pertinent to mention here that both of these complexes possess the picrate anion in their coordination sphere. The less extent of H-bonding is reported in the crystallographic description of these complexes [35]. The theoretical absorption band appears at 3223 and 3235 cm−1 for both complexes (1) and (6) whereas the experimental band is reported at 3300 cm−1 for both of them [35].
Assignments (cm−1) | [Ca(THEEN)(PIC)]+ (1) | [Ca(THPEN)(H2O)2]2+ (2) | Ba(THPEN)(PIC)2 (3) | |||
---|---|---|---|---|---|---|
Theo. | Exp. | Theo. | Exp. | Theo. | Exp. | |
ν (NO2) | 1363.56 | 1360 m | 1320.81 | 1360 vs | 1384.20 | 1370 |
δ (〓CH) | 696.80 | 700 m | 784.16 | 790 m | 800 | 800 |
Comparison of calculated and experimental IR spectral data for complexes (1–3).
Assignments (cm−1) | [Na(THPEN)]22+ (4) | [Sr(THPEN)(H2O)2]22+ (5) | [Ba(THPEN)(H2O)2]22+ (6) | |||
---|---|---|---|---|---|---|
Theo. | Exp. | Theo. | Exp. | Theo. | Exp. | |
ν (NO2) | 1366 | 1371.21 | 1330 | 1329.24 | 1340 | 1329.43 |
δ (〓CH) | 790 | 784.54 | 760 | 762.52 | 790 | 787.17 |
Comparison of calculated and experimental IR spectral data for complexes (4–6).
The coordination number of the title s-block complexes is varying from 7 to 10 in the present work. As the size of the metal increases, coordination number of central metal ion also increases. Out of the six complexes presented, three are monomeric (1–3) and three are dimeric (4–6). The longer distances between two M…M distances in the dinuclear complexes indicate the existence of van der Waals contacts between the two s-block metal ions. All the title complexes are cationic except Ba(THPEN)(PIC)2 (3). The latter is tight ion-paired complex. All strain energy minimized structures obtained using quantum-chemical approach reproduced the observed X-ray structures with geometric parameters in well agreement. HOMO-LUMO studies suggest the softness of the title s-block complexes relative to the similar already reported copper, silver and lanthanoid complexes. The theoretical spectral data (13C-NMR and IR) computed using DFT and experimental data is fairly in agreement with each other. The accuracy of the results predicts that the DFT studies performed using B3LYP/6-31 g + (d,p)/LANL2DZ level of theory is the appropriate quantum-chemical method for reproducing the experimental results for the title s-block complexes. This quantum-chemical approach has potential for molecular modeling of other s-block complexes and exploring their chemistry.
Small deviations in geometric as well as spectral parameters may be attributed to the lack of H-bonding and packing interactions within lattice which were not modeled during the computational study of the entitled s-block complexes. Moreover, the quantum-chemical approach of DFT studies has been carried out in the gaseous phase whereas the already reported experimental crystal and IR spectral data is in the solid phase while 13C-NMR spectral data is in the solution phase.
Plot showing the deviations of theoretical and experimental (a) bond lengths (Å) and (b) bond angles (°) for the complex (1) and (c) (HOMO-LUMO) of the complex (1) with energy gap.
Plot showing the deviations of theoretical and experimental (a) bond lengths (Å) and (b) bond angles (°) for the complex (2) (c) (HOMO-LUMO) of the complex (2) with energy gap.
Plot showing the deviations of theoretical and experimental (a) bond lengths (Å) and (b) bond angles (°) for the complex (3) (c) (HOMO-LUMO) of the complex (3) with energy gap.
Plot showing the deviations of theoretical and experimental (a) bond lengths (Å) and (b) bond angles (°) for the complex (4) (c) (HOMO-LUMO) of the complex (4) with energy gap.
Plot showing the deviations of theoretical and experimental (a) bond lengths (Å) and (b) bond angles (°) for the complex (5) (c) (HOMO-LUMO) of the complex (5) with energy gap.
Plot showing the deviations of theoretical and experimental (a) bond lengths (Å) and (b) bond angles (°) for the complex (6) (c) (HOMO-LUMO) of the complex (6) with energy gap.
R = H, THEEN; R = CH3, THPEN.
Bond distances (Å) | Theoretical | Experimental | Dev. | Bond angles (°) | Theoretical | Experimental | Dev. |
---|---|---|---|---|---|---|---|
Complex (1) | |||||||
Ca-N1 | 2.600 | 2.600 | 0.000 | N1-Ca-N1A | 71.54 | 71.60 | 0.06 |
Ca-O1 | 2.387 | 2.388 | 0.001 | N1-Ca-O2A | 81.41 | 65.52 | 15.89 |
Ca-O2 | 2.495 | 2.496 | 0.001 | N1-Ca-O1W | 119.08 | 119.09 | 0.01 |
Ca-O1W | 2.439 | 2.439 | 0.000 | N1-Ca-O1WA | 143.89 | 143.89 | 0.00 |
O1-Ca-O2 | 102.93 | 102.95 | 0.02 | ||||
O1-Ca-N1 | 67.80 | 67.79 | 0.01 | ||||
O1-Ca-O1W | 79.82 | 79.85 | 0.03 | ||||
O1-Ca-N1A | 132.22 | 132.22 | 0.00 | ||||
O1-Ca-O2A | 84.37 | 84.36 | 0.01 | ||||
O1-Ca-O1A | 159.11 | 159.10 | 0.01 | ||||
O1-Ca-O1WA | 83.52 | 83.54 | 0.02 | ||||
O2-Ca-N1 | 65.50 | 65.52 | 0.02 | ||||
O2-Ca-O1W | 74.11 | 74.10 | 0.01 | ||||
O2-Ca-N1A | 81.42 | 81.40 | 0.02 | ||||
O2-Ca-O2A | 139.33 | 139.89 | 0.56 | ||||
O2A-Ca-O1W | 145.88 | 145.90 | 0.02 | ||||
Complex (2) | |||||||
Ca-O1 | 2.45 | 2.41 | 0.04 | O1-Ca-O2 | 94.43 | 102.08 | 7.65 |
Ca-O2 | 2.45 | 2.38 | 0.07 | O1-Ca-O3 | 172.00 | 175.21 | 3.21 |
Ca-O3 | 2.41 | 2.48 | 0.07 | O1-Ca-O4 | 85.56 | 74.35 | 11.21 |
Ca-O4 | 2.41 | 2.37 | 0.04 | O1-Ca-O12 | 107.80 | 104.18 | 3.62 |
Ca-O12 | 2.31 | 2.30 | 0.01 | O1-Ca-O13 | 61.91 | 64.85 | 2.94 |
Ca-O13 | 2.47 | 2.73 | 0.26 | O1-Ca-N1 | 65.93 | 68.50 | 2.57 |
Ca-N1 | 2.74 | 2.59 | 0.15 | O1-Ca-N2 | 104.33 | 115.49 | 11.16 |
Ca-N2 | 2.82 | 2.65 | 0.17 | O2-Ca-O3 | 90.99 | 79.27 | 11.72 |
O2-Ca-O4 | 180.00 | 168.65 | 11.35 | ||||
O2-Ca-O12 | 108.06 | 107.20 | 0.86 | ||||
O2-Ca-O13 | 61.38 | 69.92 | 8.54 | ||||
O2-Ca-N1 | 64.20 | 68.43 | 4.23 | ||||
O2-Ca-N2 | 114.39 | 105.72 | 8.67 | ||||
O3-Ca-O4 | 89.01 | 105.24 | 16.23 | ||||
O3-Ca-O12 | 75.95 | 71.06 | 4.89 | ||||
O3-Ca-O13 | 126.03 | 110.69 | 15.34 | ||||
O3-Ca-N1 | 111.54 | 116.18 | 4.64 | ||||
O3-Ca-N2 | 67.97 | 68.26 | 0.29 | ||||
O4-Ca-O12 | 71.93 | 84.20 | 12.27 | ||||
O4-Ca-O13 | 118.62 | 116.91 | 1.71 | ||||
O4-Ca-N1 | 115.80 | 100.38 | 15.42 | ||||
O4-Ca-N2 | 65.61 | 67.36 | 1.75 | ||||
O12-Ca-O13 | 71.32 | 62.19 | 9.13 | ||||
O12-Ca-N1 | 168.56 | 169.55 | 0.99 | ||||
O12-Ca-N2 | 123.47 | 120.54 | 2.93 | ||||
O13-Ca-N1 | 97.26 | 107.46 | 10.2 | ||||
O13-Ca-N2 | 163.73 | 175.60 | 11.87 | ||||
N1-Ca-N2 | 67.95 | 69.92 | 1.97 | ||||
Complex (3) | |||||||
Ba-O1 | 2.720 | 2.720 | 0.000 | O1-Ba-O2 | 86.95 | 87.00 | 0.05 |
Ba-O2 | 2.807 | 2.801 | 0.006 | O1-Ba-O3 | 172.87 | 173.00 | 0.13 |
Ba-O3 | 2.753 | 2.750 | 0.003 | O1-Ba-O4 | 88.55 | 88.50 | 0.05 |
Ba-O4 | 2.812 | 2.812 | 0.000 | O1-Ba-O6 | 72.90 | 72.90 | 0.00 |
Ba-O5 | 2.681 | 2.683 | 0.002 | O1-Ba-O12 | 61.79 | 61.80 | 0.01 |
Ba-O6 | 3.127 | 3.128 | 0.001 | O1-Ba-O18 | 109.63 | 109.70 | 0.07 |
Ba-O12 | 2.728 | 2.729 | 0.001 | O1-Ba-N1 | 58.12 | 58.10 | 0.02 |
Ba-O18 | 2.977 | 2.979 | 0.002 | O1-Ba-N2 | 114.85 | 114.80 | 0.05 |
Ba-N1 | 3.038 | 3.038 | 0.000 | O2-Ba-O4 | 129.37 | 129.40 | 0.03 |
Ba-N2 | 3.026 | 3.028 | 0.002 | O2-Ba-O6 | 64.79 | 64.80 | 0.01 |
O2-Ba-O18 | 161.62 | 160.60 | 0.02 | ||||
O2-Ba-N2 | 79.36 | 79.40 | 0.03 | ||||
O2-Ba-N1 | 57.03 | 57.12 | 0.05 | ||||
O3-Ba-O2 | 92.08 | 92.10 | 0.02 | ||||
O3-Ba-O4 | 86.61 | 86.70 | 0.09 | ||||
O3-Ba-O6 | 113.02 | 113.10 | 0.08 | ||||
O3-Ba-O18 | 72.70 | 72.80 | 0.10 | ||||
O3-Ba-N1 | 115.63 | 115.60 | 0.03 | ||||
O3-Ba-N2 | 58.06 | 58.20 | 0.14 | ||||
O4-Ba-O6 | 156.82 | 156.80 | 0.02 | ||||
O4-Ba-O18 | 63.13 | 63.20 | 0.07 | ||||
O4-Ba-N1 | 78.20 | 78.20 | 0.00 | ||||
O4-Ba-N2 | 57.43 | 57.40 | 0.03 | ||||
O5-Ba-O1 | 123.12 | 123.20 | 0.08 | ||||
O5-Ba-O2 | 85.94 | 85.90 | 0.04 | ||||
O5-Ba-O3 | 63.80 | 63.90 | 0.10 | ||||
O5-Ba-O4 | 135.92 | 135.90 | 0.02 | ||||
O5-Ba-O6 | 53.26 | 53.30 | 0.03 | ||||
O5-Ba-O12 | 84.0 | 84.00 | 0.00 | ||||
O5-Ba-O18 | 76.67 | 76.90 | 0.13 | ||||
O5-Ba-N1 | 142.90 | 142.90 | 0.00 | ||||
O5-Ba-N2 | 118.97 | 118.90 | 0.07 | ||||
O12-Ba-O2 | 133.15 | 133.20 | 0.05 | ||||
O12-Ba-O3 | 123.02 | 123.00 | 0.02 | ||||
O12-Ba-O4 | 86.45 | 86.40 | 0.05 | ||||
O12-Ba-O6 | 72.69 | 72.70 | 0.01 | ||||
O12-Ba-O18 | 54.05 | 54.00 | 0.05 | ||||
O12-Ba-N1 | 117.95 | 117.96 | 0.01 | ||||
O12-Ba-N2 | 143.78 | 143.80 | 0.02 | ||||
O18-Ba-O6 | 109.54 | 109.60 | 0.06 | ||||
O18-Ba-N1 | 140.27 | 140.40 | 0.13 | ||||
O18-Ba-N2 | 101.49 | 101.50 | 0.01 | ||||
N2-Ba-N1 | 61.27 | 61.30 | 0.03 | ||||
N2-Ba-O6 | 143.21 | 143.20 | 0.01 | ||||
N1-Ba-O6 | 102.39 | 102.40 | 0.01 | ||||
Complex (4) | |||||||
Na-N1 | 2.552 | 2.554 | 0.002 | O1-Na-O2 | 99.56 | 99.50 | 0.06 |
Na-N2 | 2.565 | 2.566 | 0.001 | O1-Na-O3 | 86.59 | 86.60 | 0.01 |
Na-O1 | 2.412 | 2.412 | 0.000 | O1-Na-O4 | 174.34 | 174.30 | 0.04 |
Na-O2 | 2.393 | 2.393 | 0.000 | O1-Na-O4A | 90.18 | 9023 | 0.05 |
Na-O3 | 2.505 | 2.505 | 0.000 | O1-Na-N1 | 69.82 | 69.82 | 0.00 |
Na-O4 | 2.628 | 2.629 | 0.001 | O1-Na-N2 | 109.13 | 109.10 | 0.03 |
Na-O4A | 2.442 | 2.443 | 0.001 | O2-Na-O3 | 164.10 | 164.13 | 0.03 |
Na-NaA | 3.429 | 3.430 | 0.001 | O2-Na-O4 | 78.26 | 78.31 | 0.05 |
O2-Na-O4A | 88.56 | 88.57 | 0.01 | ||||
O2-Na-N1 | 70.69 | 70.70 | 0.01 | ||||
O2-Na-N2 | 121.68 | 121.71 | 0.03 | ||||
O3-Na-O4 | 96.86 | 96.87 | 0.01 | ||||
O3-Na-N1 | 125.19 | 125.17 | 0.02 | ||||
O3-Na-N2 | 68.93 | 68.91 | 0.02 | ||||
O3-Na-O4A | 76.69 | 76.72 | 0.03 | ||||
O4-Na-O4A | 94.96 | 95.00 | 0.03 | ||||
O4-Na-N1 | 68.25 | 68.25 | 0.00 | ||||
O4-Na-N2 | 68.25 | 68.25 | 0.00 | ||||
N1-Na-N2 | 73.38 | 73.37 | 0.01 | ||||
N1-Na-O4A | 147.48 | 147.51 | 0.03 | ||||
N2-Na-O4A | 138.85 | 138.87 | 0.02 | ||||
Complex(5) | |||||||
Sr-O1 | 2.617 | 2.618 | 0.001 | O3-Sr-O2 | 151.28 | 158.70 | 7.42 |
Sr-O2 | 2.611 | 2.610 | 0.001 | O3-Sr-O1 | 73.24 | 77.20 | 3.96 |
Sr-O3 | 2.506 | 2.505 | 0.001 | O2-Sr-O1 | 113.98 | 114.30 | 0.32 |
Sr-O4 | 2.618 | 2.618 | 0.000 | O3-Sr-O4 | 87.91 | 88.20 | 0.29 |
Sr-O1W | 2.701 | 2.702 | 0.001 | O2-Sr-O4 | 77.89 | 73.50 | 4.39 |
Sr-O2W | 2.699 | 2.699 | 0.000 | O1-Sr-O4 | 158.36 | 151.60 | 6.76 |
Sr-O2WA | 2.726 | 2.699 | 0.000 | O3-Sr-N1 | 102.34 | 113.60 | 11.26 |
Sr-N1 | 2.835 | 2.835 | 0.000 | O4-Sr-N1 | 113.34 | 102.50 | 10.84 |
Sr-N2 | 2.849 | 2.849 | 0.000 | O3-Sr-N2 | 61.38 | 64.40 | 3.02 |
O2-Sr-N2 | 89.92 | 97.10 | 7.18 | ||||
O1-Sr-N2 | 96.80 | 90.2 | 6.60 | ||||
O4-Sr-N2 | 64.13 | 61.60 | 2.53 | ||||
O3-Sr-O2W | 106.07 | 106.40 | 0.33 | ||||
O2-Sr-O2W | 70.58 | 77.10 | 6.52 | ||||
O1-Sr-O2W | 129.35 | 140.50 | 11.15 | ||||
O4-Sr-O2W | 70.80 | 67.90 | 2.90 | ||||
O2-Sr-O1W | 79.52 | 65.40 | 14.12 | ||||
O1-Sr-O1W | 65.11 | 79.80 | 14.69 | ||||
O4-Sr-O1W | 136.42 | 127.40 | 9.02 | ||||
O3’-Sr-O1W | 126.14 | 127.90 | 1.76 | ||||
O2W-Sr-O1W | 70.75 | 71.00 | 0.25 | ||||
O2W-Sr-N2 | 128.11 | 128.40 | 0.29 | ||||
O1W-Sr-N2 | 152.06 | 152.40 | 0.34 | ||||
N1-Sr-N2 | 64.77 | 65.00 | 0.23 | ||||
O2W-Sr-N1 | 139.03 | 139.30 | 0.27 | ||||
O1W-Sr-N1 | 87.52 | 87.80 | 0.28 | ||||
Complex (6) | |||||||
Ba-O1 | 2.736 | 2.738 | 0.002 | O4-Ba-O1 | 162.70 | 162.90 | 0.20 |
Ba-O2 | 2.763 | 2.761 | 0.002 | O4-Ba-O3 | 92.45 | 92.70 | 0.25 |
Ba-O3 | 2.756 | 2.757 | 0.001 | O1-Ba-O3 | 79.69 | 80.00 | 0.31 |
Ba-O4 | 2.658 | 2.657 | 0.001 | O4-Ba-O2 | 84.25 | 84.60 | 0.35 |
Ba-O1W | 2.880 | 2.880 | 0.000 | O1-Ba-O2 | 94.22 | 94.50 | 0.28 |
Ba-O2W | 2.988 | 2.990 | -0.002 | O3-Ba-O2 | 148.19 | 148.40 | 0.21 |
Ba-N1 | 3.009 | 3.002 | 0.007 | O4-Ba-N1 | 107.19 | 107.50 | 0.31 |
Ba-N2 | 3.010 | 3.004 | 0.006 | O1-Ba-N1 | 58.19 | 58.40 | 0.21 |
O3-Ba-N1 | 91.90 | 92.00 | 0.01 | ||||
O2-Ba-N1 | 59.43 | 59.60 | 0.17 | ||||
O4-Ba-N2 | 59.95 | 61.10 | 1.15 | ||||
O1-Ba-N2 | 103.03 | 103.20 | 0.17 | ||||
O3-Ba-N2 | 58.68 | 58.80 | 0.12 | ||||
O2-Ba-N2 | 93.2 | 93.40 | 0.20 | ||||
N1-Ba-N2 | 61.84 | 62.00 | 0.16 | ||||
O4-Ba-O1W | 126.17 | 126.50 | 0.33 | ||||
O1-Ba-O1W | 66.29 | 66.50 | 0.23 | ||||
O3-Ba-O1W | 72.53 | 72.80 | 0.27 | ||||
O2-Ba-O1W | 133.50 | 133.80 | 0.30 | ||||
O1-Ba-O2W | 73.43 | 73.70 | 0.27 | ||||
O3-Ba-O2W | 131.18 | 131.50 | 0.32 | ||||
O2-Ba-O2W | 74.74 | 75.00 | 0.26 | ||||
O2W-Ba-O1WA | 59.36 | 59.50 | 0.14 | ||||
N1-Ba-O1WA | 137.03 | 137.20 | 0.17 | ||||
N1-Ba-O1W | 124.19 | 124.19 | 0.00 | ||||
N1-Ba-O2W | 106.68 | 106.90 | 0.22 | ||||
N2-Ba-O1WA | 123.73 | 124.00 | 0.27 | ||||
N2-Ba-O1W | 131.21 | 131.50 | 0.29 | ||||
N2-Ba-O2W | 166.91 | 167.00 | 0.10 | ||||
N2-Ba-O2WA | 100.84 | 100.87 | 0.03 |
Comparison of selected experimental and calculated geometric parameters bond lengths (Å) and bond angles (°) for complexes (1–6).
IntechOpen aims to ensure that original material is published while at the same time giving significant freedom to our Authors. To that end we maintain a flexible Copyright Policy guaranteeing that there is no transfer of copyright to the publisher and Authors retain exclusive copyright to their Work.
',metaTitle:"Publication Agreement - Chapters",metaDescription:"IN TECH aims to guarantee that original material is published while at the same time giving significant freedom to our authors. For that matter, we uphold a flexible copyright policy meaning that there is no transfer of copyright to the publisher and authors retain exclusive copyright to their work.\n\nWhen submitting a manuscript the Corresponding Author is required to accept the terms and conditions set forth in our Publication Agreement as follows:",metaKeywords:null,canonicalURL:"/page/publication-agreement-chapters",contentRaw:'[{"type":"htmlEditorComponent","content":"The Corresponding Author (acting on behalf of all Authors) and INTECHOPEN LIMITED, incorporated and registered in England and Wales with company number 11086078 and a registered office at 5 Princes Gate Court, London, United Kingdom, SW7 2QJ conclude the following Agreement regarding the publication of a Book Chapter:
\\n\\n1. DEFINITIONS
\\n\\nCorresponding Author: The Author of the Chapter who serves as a Signatory to this Agreement. The Corresponding Author acts on behalf of any other Co-Author.
\\n\\nCo-Author: All other Authors of the Chapter besides the Corresponding Author.
\\n\\nIntechOpen: IntechOpen Ltd., the Publisher of the Book.
\\n\\nBook: The publication as a collection of chapters compiled by IntechOpen including the Chapter. Chapter: The original literary work created by Corresponding Author and any Co-Author that is the subject of this Agreement.
\\n\\n2. CORRESPONDING AUTHOR'S GRANT OF RIGHTS
\\n\\n2.1 Subject to the following Article, the Corresponding Author grants and shall ensure that each Co-Author grants, to IntechOpen, during the full term of copyright and any extensions or renewals of that term the following:
\\n\\nThe aforementioned licenses shall survive the expiry or termination of this Agreement for any reason.
\\n\\n2.2 The Corresponding Author (on their own behalf and on behalf of any Co-Author) reserves the following rights to the Chapter but agrees not to exercise them in such a way as to adversely affect IntechOpen's ability to utilize the full benefit of this Publication Agreement: (i) reprographic rights worldwide, other than those which subsist in the typographical arrangement of the Chapter as published by IntechOpen; and (ii) public lending rights arising under the Public Lending Right Act 1979, as amended from time to time, and any similar rights arising in any part of the world.
\\n\\nThe Corresponding Author confirms that they (and any Co-Author) are and will remain a member of any applicable licensing and collecting society and any successor to that body responsible for administering royalties for the reprographic reproduction of copyright works.
\\n\\nSubject to the license granted above, copyright in the Chapter and all versions of it created during IntechOpen's editing process (including the published version) is retained by the Corresponding Author and any Co-Author.
\\n\\nSubject to the license granted above, the Corresponding Author and any Co-Author retains patent, trademark and other intellectual property rights to the Chapter.
\\n\\n2.3 All rights granted to IntechOpen in this Article are assignable, sublicensable or otherwise transferrable to third parties without the Corresponding Author's or any Co-Author’s specific approval.
\\n\\n2.4 The Corresponding Author (on their own behalf and on behalf of each Co-Author) will not assert any rights under the Copyright, Designs and Patents Act 1988 to object to derogatory treatment of the Chapter as a consequence of IntechOpen's changes to the Chapter arising from translation of it, corrections and edits for house style, removal of problematic material and other reasonable edits.
\\n\\n3. CORRESPONDING AUTHOR'S DUTIES
\\n\\n3.1 When distributing or re-publishing the Chapter, the Corresponding Author agrees to credit the Book in which the Chapter has been published as the source of first publication, as well as IntechOpen. The Corresponding Author warrants that each Co-Author will also credit the Book in which the Chapter has been published as the source of first publication, as well as IntechOpen, when they are distributing or re-publishing the Chapter.
\\n\\n3.2 When submitting the Chapter, the Corresponding Author agrees to:
\\n\\nThe Corresponding Author will be held responsible for the payment of the Open Access Publishing Fees.
\\n\\nAll payments shall be due 30 days from the date of the issued invoice. The Corresponding Author or the payer on the Corresponding Author's and Co-Authors' behalf will bear all banking and similar charges incurred.
\\n\\n3.3 The Corresponding Author shall obtain in writing all consents necessary for the reproduction of any material in which a third-party right exists, including quotations, photographs and illustrations, in all editions of the Chapter worldwide for the full term of the above licenses, and shall provide to IntechOpen upon request the original copies of such consents for inspection (at IntechOpen's option) or photocopies of such consents.
\\n\\nThe Corresponding Author shall obtain written informed consent for publication from people who might recognize themselves or be identified by others (e.g. from case reports or photographs).
\\n\\n3.4 The Corresponding Author and any Co-Author shall respect confidentiality rights during and after the termination of this Agreement. The information contained in all correspondence and documents as part of the publishing activity between IntechOpen and the Corresponding Author and any Co-Author are confidential and are intended only for the recipient. The contents may not be disclosed publicly and are not intended for unauthorized use or distribution. Any use, disclosure, copying, or distribution is prohibited and may be unlawful.
\\n\\n4. CORRESPONDING AUTHOR'S WARRANTY
\\n\\n4.1 The Corresponding Author represents and warrants that the Chapter does not and will not breach any applicable law or the rights of any third party and, specifically, that the Chapter contains no matter that is defamatory or that infringes any literary or proprietary rights, intellectual property rights, or any rights of privacy. The Corresponding Author warrants and represents that: (i) the Chapter is the original work of themselves and any Co-Author and is not copied wholly or substantially from any other work or material or any other source; (ii) the Chapter has not been formally published in any other peer-reviewed journal or in a book or edited collection, and is not under consideration for any such publication; (iii) they themselves and any Co-Author are qualifying persons under section 154 of the Copyright, Designs and Patents Act 1988; (iv) they themselves and any Co-Author have not assigned and will not during the term of this Publication Agreement purport to assign any of the rights granted to IntechOpen under this Publication Agreement; and (v) the rights granted by this Publication Agreement are free from any security interest, option, mortgage, charge or lien.
\\n\\nThe Corresponding Author also warrants and represents that: (i) they have the full power to enter into this Publication Agreement on their own behalf and on behalf of each Co-Author; and (ii) they have the necessary rights and/or title in and to the Chapter to grant IntechOpen, on behalf of themselves and any Co-Author, the rights and licenses expressed to be granted in this Publication Agreement. If the Chapter was prepared jointly by the Corresponding Author and any Co-Author, the Corresponding Author warrants and represents that: (i) each Co-Author agrees to the submission, license and publication of the Chapter on the terms of this Publication Agreement; and (ii) they have the authority to enter into this Publication Agreement on behalf of and bind each Co-Author. The Corresponding Author shall: (i) ensure each Co-Author complies with all relevant provisions of this Publication Agreement, including those relating to confidentiality, performance and standards, as if a party to this Publication Agreement; and (ii) remain primarily liable for all acts and/or omissions of each such Co-Author.
\\n\\nThe Corresponding Author agrees to indemnify and hold IntechOpen harmless against all liabilities, costs, expenses, damages and losses and all reasonable legal costs and expenses suffered or incurred by IntechOpen arising out of or in connection with any breach of the aforementioned representations and warranties. This indemnity shall not cover IntechOpen to the extent that a claim under it results from IntechOpen's negligence or willful misconduct.
\\n\\n4.2 Nothing in this Publication Agreement shall have the effect of excluding or limiting any liability for death or personal injury caused by negligence or any other liability that cannot be excluded or limited by applicable law.
\\n\\n5. TERMINATION
\\n\\n5.1 IntechOpen has a right to terminate this Publication Agreement for quality, program, technical or other reasons with immediate effect, including without limitation (i) if the Corresponding Author or any Co-Author commits a material breach of this Publication Agreement; (ii) if the Corresponding Author or any Co-Author (being an individual) is the subject of a bankruptcy petition, application or order; or (iii) if the Corresponding Author or any Co-Author (being a company) commences negotiations with all or any class of its creditors with a view to rescheduling any of its debts, or makes a proposal for or enters into any compromise or arrangement with any of its creditors.
\\n\\nIn case of termination, IntechOpen will notify the Corresponding Author, in writing, of the decision.
\\n\\n6. INTECHOPEN’S DUTIES AND RIGHTS
\\n\\n6.1 Unless prevented from doing so by events outside its reasonable control, IntechOpen, in its discretion, agrees to publish the Chapter attributing it to the Corresponding Author and any Co-Author.
\\n\\n6.2 IntechOpen has the right to use the Corresponding Author’s and any Co-Author’s names and likeness in connection with scientific dissemination, retrieval, archiving, web hosting and promotion and marketing of the Chapter and has the right to contact the Corresponding Author and any Co-Author until the Chapter is publicly available on any platform owned and/or operated by IntechOpen.
\\n\\n6.3 IntechOpen is granted the authority to enforce the rights from this Publication Agreement, on behalf of the Corresponding Author and any Co-Author, against third parties (for example in cases of plagiarism or copyright infringements). In respect of any such infringement or suspected infringement of the copyright in the Chapter, IntechOpen shall have absolute discretion in addressing any such infringement which is likely to affect IntechOpen's rights under this Publication Agreement, including issuing and conducting proceedings against the suspected infringer.
\\n\\n7. MISCELLANEOUS
\\n\\n7.1 Further Assurance: The Corresponding Author shall and will ensure that any relevant third party (including any Co-Author) shall, execute and deliver whatever further documents or deeds and perform such acts as IntechOpen reasonably requires from time to time for the purpose of giving IntechOpen the full benefit of the provisions of this Publication Agreement.
\\n\\n7.2 Third Party Rights: A person who is not a party to this Publication Agreement may not enforce any of its provisions under the Contracts (Rights of Third Parties) Act 1999.
\\n\\n7.3 Entire Agreement: This Publication Agreement constitutes the entire agreement between the parties in relation to its subject matter. It replaces and extinguishes all prior agreements, draft agreements, arrangements, collateral warranties, collateral contracts, statements, assurances, representations and undertakings of any nature made by or on behalf of the parties, whether oral or written, in relation to that subject matter. Each party acknowledges that in entering into this Publication Agreement it has not relied upon any oral or written statements, collateral or other warranties, assurances, representations or undertakings which were made by or on behalf of the other party in relation to the subject matter of this Publication Agreement at any time before its signature (together "Pre-Contractual Statements"), other than those which are set out in this Publication Agreement. Each party hereby waives all rights and remedies which might otherwise be available to it in relation to such Pre-Contractual Statements. Nothing in this clause shall exclude or restrict the liability of either party arising out of its pre-contract fraudulent misrepresentation or fraudulent concealment.
\\n\\n7.4 Waiver: No failure or delay by a party to exercise any right or remedy provided under this Publication Agreement or by law shall constitute a waiver of that or any other right or remedy, nor shall it preclude or restrict the further exercise of that or any other right or remedy. No single or partial exercise of such right or remedy shall preclude or restrict the further exercise of that or any other right or remedy.
\\n\\n7.5 Variation: No variation of this Publication Agreement shall be effective unless it is in writing and signed by the parties (or their duly authorized representatives).
\\n\\n7.6 Severance: If any provision or part-provision of this Publication Agreement is or becomes invalid, illegal or unenforceable, it shall be deemed modified to the minimum extent necessary to make it valid, legal and enforceable. If such modification is not possible, the relevant provision or part-provision shall be deemed deleted.
\\n\\nAny modification to or deletion of a provision or part-provision under this clause shall not affect the validity and enforceability of the rest of this Publication Agreement.
\\n\\n7.7 No partnership: Nothing in this Publication Agreement is intended to, or shall be deemed to, establish or create any partnership or joint venture or the relationship of principal and agent or employer and employee between IntechOpen and the Corresponding Author or any Co-Author, nor authorize any party to make or enter into any commitments for or on behalf of any other party.
\\n\\n7.8 Governing law: This Publication Agreement and any dispute or claim (including non-contractual disputes or claims) arising out of or in connection with it or its subject matter or formation shall be governed by and construed in accordance with the law of England and Wales. The parties submit to the exclusive jurisdiction of the English courts to settle any dispute or claim arising out of or in connection with this Publication Agreement (including any non-contractual disputes or claims).
\\n\\nLast updated: 2020-11-27
\\n\\n\\n\\n
\\n"}]'},components:[{type:"htmlEditorComponent",content:"
The Corresponding Author (acting on behalf of all Authors) and INTECHOPEN LIMITED, incorporated and registered in England and Wales with company number 11086078 and a registered office at 5 Princes Gate Court, London, United Kingdom, SW7 2QJ conclude the following Agreement regarding the publication of a Book Chapter:
\n\n1. DEFINITIONS
\n\nCorresponding Author: The Author of the Chapter who serves as a Signatory to this Agreement. The Corresponding Author acts on behalf of any other Co-Author.
\n\nCo-Author: All other Authors of the Chapter besides the Corresponding Author.
\n\nIntechOpen: IntechOpen Ltd., the Publisher of the Book.
\n\nBook: The publication as a collection of chapters compiled by IntechOpen including the Chapter. Chapter: The original literary work created by Corresponding Author and any Co-Author that is the subject of this Agreement.
\n\n2. CORRESPONDING AUTHOR'S GRANT OF RIGHTS
\n\n2.1 Subject to the following Article, the Corresponding Author grants and shall ensure that each Co-Author grants, to IntechOpen, during the full term of copyright and any extensions or renewals of that term the following:
\n\nThe aforementioned licenses shall survive the expiry or termination of this Agreement for any reason.
\n\n2.2 The Corresponding Author (on their own behalf and on behalf of any Co-Author) reserves the following rights to the Chapter but agrees not to exercise them in such a way as to adversely affect IntechOpen's ability to utilize the full benefit of this Publication Agreement: (i) reprographic rights worldwide, other than those which subsist in the typographical arrangement of the Chapter as published by IntechOpen; and (ii) public lending rights arising under the Public Lending Right Act 1979, as amended from time to time, and any similar rights arising in any part of the world.
\n\nThe Corresponding Author confirms that they (and any Co-Author) are and will remain a member of any applicable licensing and collecting society and any successor to that body responsible for administering royalties for the reprographic reproduction of copyright works.
\n\nSubject to the license granted above, copyright in the Chapter and all versions of it created during IntechOpen's editing process (including the published version) is retained by the Corresponding Author and any Co-Author.
\n\nSubject to the license granted above, the Corresponding Author and any Co-Author retains patent, trademark and other intellectual property rights to the Chapter.
\n\n2.3 All rights granted to IntechOpen in this Article are assignable, sublicensable or otherwise transferrable to third parties without the Corresponding Author's or any Co-Author’s specific approval.
\n\n2.4 The Corresponding Author (on their own behalf and on behalf of each Co-Author) will not assert any rights under the Copyright, Designs and Patents Act 1988 to object to derogatory treatment of the Chapter as a consequence of IntechOpen's changes to the Chapter arising from translation of it, corrections and edits for house style, removal of problematic material and other reasonable edits.
\n\n3. CORRESPONDING AUTHOR'S DUTIES
\n\n3.1 When distributing or re-publishing the Chapter, the Corresponding Author agrees to credit the Book in which the Chapter has been published as the source of first publication, as well as IntechOpen. The Corresponding Author warrants that each Co-Author will also credit the Book in which the Chapter has been published as the source of first publication, as well as IntechOpen, when they are distributing or re-publishing the Chapter.
\n\n3.2 When submitting the Chapter, the Corresponding Author agrees to:
\n\nThe Corresponding Author will be held responsible for the payment of the Open Access Publishing Fees.
\n\nAll payments shall be due 30 days from the date of the issued invoice. The Corresponding Author or the payer on the Corresponding Author's and Co-Authors' behalf will bear all banking and similar charges incurred.
\n\n3.3 The Corresponding Author shall obtain in writing all consents necessary for the reproduction of any material in which a third-party right exists, including quotations, photographs and illustrations, in all editions of the Chapter worldwide for the full term of the above licenses, and shall provide to IntechOpen upon request the original copies of such consents for inspection (at IntechOpen's option) or photocopies of such consents.
\n\nThe Corresponding Author shall obtain written informed consent for publication from people who might recognize themselves or be identified by others (e.g. from case reports or photographs).
\n\n3.4 The Corresponding Author and any Co-Author shall respect confidentiality rights during and after the termination of this Agreement. The information contained in all correspondence and documents as part of the publishing activity between IntechOpen and the Corresponding Author and any Co-Author are confidential and are intended only for the recipient. The contents may not be disclosed publicly and are not intended for unauthorized use or distribution. Any use, disclosure, copying, or distribution is prohibited and may be unlawful.
\n\n4. CORRESPONDING AUTHOR'S WARRANTY
\n\n4.1 The Corresponding Author represents and warrants that the Chapter does not and will not breach any applicable law or the rights of any third party and, specifically, that the Chapter contains no matter that is defamatory or that infringes any literary or proprietary rights, intellectual property rights, or any rights of privacy. The Corresponding Author warrants and represents that: (i) the Chapter is the original work of themselves and any Co-Author and is not copied wholly or substantially from any other work or material or any other source; (ii) the Chapter has not been formally published in any other peer-reviewed journal or in a book or edited collection, and is not under consideration for any such publication; (iii) they themselves and any Co-Author are qualifying persons under section 154 of the Copyright, Designs and Patents Act 1988; (iv) they themselves and any Co-Author have not assigned and will not during the term of this Publication Agreement purport to assign any of the rights granted to IntechOpen under this Publication Agreement; and (v) the rights granted by this Publication Agreement are free from any security interest, option, mortgage, charge or lien.
\n\nThe Corresponding Author also warrants and represents that: (i) they have the full power to enter into this Publication Agreement on their own behalf and on behalf of each Co-Author; and (ii) they have the necessary rights and/or title in and to the Chapter to grant IntechOpen, on behalf of themselves and any Co-Author, the rights and licenses expressed to be granted in this Publication Agreement. If the Chapter was prepared jointly by the Corresponding Author and any Co-Author, the Corresponding Author warrants and represents that: (i) each Co-Author agrees to the submission, license and publication of the Chapter on the terms of this Publication Agreement; and (ii) they have the authority to enter into this Publication Agreement on behalf of and bind each Co-Author. The Corresponding Author shall: (i) ensure each Co-Author complies with all relevant provisions of this Publication Agreement, including those relating to confidentiality, performance and standards, as if a party to this Publication Agreement; and (ii) remain primarily liable for all acts and/or omissions of each such Co-Author.
\n\nThe Corresponding Author agrees to indemnify and hold IntechOpen harmless against all liabilities, costs, expenses, damages and losses and all reasonable legal costs and expenses suffered or incurred by IntechOpen arising out of or in connection with any breach of the aforementioned representations and warranties. This indemnity shall not cover IntechOpen to the extent that a claim under it results from IntechOpen's negligence or willful misconduct.
\n\n4.2 Nothing in this Publication Agreement shall have the effect of excluding or limiting any liability for death or personal injury caused by negligence or any other liability that cannot be excluded or limited by applicable law.
\n\n5. TERMINATION
\n\n5.1 IntechOpen has a right to terminate this Publication Agreement for quality, program, technical or other reasons with immediate effect, including without limitation (i) if the Corresponding Author or any Co-Author commits a material breach of this Publication Agreement; (ii) if the Corresponding Author or any Co-Author (being an individual) is the subject of a bankruptcy petition, application or order; or (iii) if the Corresponding Author or any Co-Author (being a company) commences negotiations with all or any class of its creditors with a view to rescheduling any of its debts, or makes a proposal for or enters into any compromise or arrangement with any of its creditors.
\n\nIn case of termination, IntechOpen will notify the Corresponding Author, in writing, of the decision.
\n\n6. INTECHOPEN’S DUTIES AND RIGHTS
\n\n6.1 Unless prevented from doing so by events outside its reasonable control, IntechOpen, in its discretion, agrees to publish the Chapter attributing it to the Corresponding Author and any Co-Author.
\n\n6.2 IntechOpen has the right to use the Corresponding Author’s and any Co-Author’s names and likeness in connection with scientific dissemination, retrieval, archiving, web hosting and promotion and marketing of the Chapter and has the right to contact the Corresponding Author and any Co-Author until the Chapter is publicly available on any platform owned and/or operated by IntechOpen.
\n\n6.3 IntechOpen is granted the authority to enforce the rights from this Publication Agreement, on behalf of the Corresponding Author and any Co-Author, against third parties (for example in cases of plagiarism or copyright infringements). In respect of any such infringement or suspected infringement of the copyright in the Chapter, IntechOpen shall have absolute discretion in addressing any such infringement which is likely to affect IntechOpen's rights under this Publication Agreement, including issuing and conducting proceedings against the suspected infringer.
\n\n7. MISCELLANEOUS
\n\n7.1 Further Assurance: The Corresponding Author shall and will ensure that any relevant third party (including any Co-Author) shall, execute and deliver whatever further documents or deeds and perform such acts as IntechOpen reasonably requires from time to time for the purpose of giving IntechOpen the full benefit of the provisions of this Publication Agreement.
\n\n7.2 Third Party Rights: A person who is not a party to this Publication Agreement may not enforce any of its provisions under the Contracts (Rights of Third Parties) Act 1999.
\n\n7.3 Entire Agreement: This Publication Agreement constitutes the entire agreement between the parties in relation to its subject matter. It replaces and extinguishes all prior agreements, draft agreements, arrangements, collateral warranties, collateral contracts, statements, assurances, representations and undertakings of any nature made by or on behalf of the parties, whether oral or written, in relation to that subject matter. Each party acknowledges that in entering into this Publication Agreement it has not relied upon any oral or written statements, collateral or other warranties, assurances, representations or undertakings which were made by or on behalf of the other party in relation to the subject matter of this Publication Agreement at any time before its signature (together "Pre-Contractual Statements"), other than those which are set out in this Publication Agreement. Each party hereby waives all rights and remedies which might otherwise be available to it in relation to such Pre-Contractual Statements. Nothing in this clause shall exclude or restrict the liability of either party arising out of its pre-contract fraudulent misrepresentation or fraudulent concealment.
\n\n7.4 Waiver: No failure or delay by a party to exercise any right or remedy provided under this Publication Agreement or by law shall constitute a waiver of that or any other right or remedy, nor shall it preclude or restrict the further exercise of that or any other right or remedy. No single or partial exercise of such right or remedy shall preclude or restrict the further exercise of that or any other right or remedy.
\n\n7.5 Variation: No variation of this Publication Agreement shall be effective unless it is in writing and signed by the parties (or their duly authorized representatives).
\n\n7.6 Severance: If any provision or part-provision of this Publication Agreement is or becomes invalid, illegal or unenforceable, it shall be deemed modified to the minimum extent necessary to make it valid, legal and enforceable. If such modification is not possible, the relevant provision or part-provision shall be deemed deleted.
\n\nAny modification to or deletion of a provision or part-provision under this clause shall not affect the validity and enforceability of the rest of this Publication Agreement.
\n\n7.7 No partnership: Nothing in this Publication Agreement is intended to, or shall be deemed to, establish or create any partnership or joint venture or the relationship of principal and agent or employer and employee between IntechOpen and the Corresponding Author or any Co-Author, nor authorize any party to make or enter into any commitments for or on behalf of any other party.
\n\n7.8 Governing law: This Publication Agreement and any dispute or claim (including non-contractual disputes or claims) arising out of or in connection with it or its subject matter or formation shall be governed by and construed in accordance with the law of England and Wales. The parties submit to the exclusive jurisdiction of the English courts to settle any dispute or claim arising out of or in connection with this Publication Agreement (including any non-contractual disputes or claims).
\n\nLast updated: 2020-11-27
\n\n\n\n
\n"}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"6700",title:"Dr.",name:"Abbass A.",middleName:null,surname:"Hashim",slug:"abbass-a.-hashim",fullName:"Abbass A. Hashim",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/6700/images/1864_n.jpg",biography:"Currently I am carrying out research in several areas of interest, mainly covering work on chemical and bio-sensors, semiconductor thin film device fabrication and characterisation.\nAt the moment I have very strong interest in radiation environmental pollution and bacteriology treatment. The teams of researchers are working very hard to bring novel results in this field. I am also a member of the team in charge for the supervision of Ph.D. students in the fields of development of silicon based planar waveguide sensor devices, study of inelastic electron tunnelling in planar tunnelling nanostructures for sensing applications and development of organotellurium(IV) compounds for semiconductor applications. I am a specialist in data analysis techniques and nanosurface structure. I have served as the editor for many books, been a member of the editorial board in science journals, have published many papers and hold many patents.",institutionString:null,institution:{name:"Sheffield Hallam University",country:{name:"United Kingdom"}}},{id:"54525",title:"Prof.",name:"Abdul Latif",middleName:null,surname:"Ahmad",slug:"abdul-latif-ahmad",fullName:"Abdul Latif Ahmad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"20567",title:"Prof.",name:"Ado",middleName:null,surname:"Jorio",slug:"ado-jorio",fullName:"Ado Jorio",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Federal de Minas Gerais",country:{name:"Brazil"}}},{id:"47940",title:"Dr.",name:"Alberto",middleName:null,surname:"Mantovani",slug:"alberto-mantovani",fullName:"Alberto Mantovani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"12392",title:"Mr.",name:"Alex",middleName:null,surname:"Lazinica",slug:"alex-lazinica",fullName:"Alex Lazinica",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/12392/images/7282_n.png",biography:"Alex Lazinica is the founder and CEO of IntechOpen. After obtaining a Master's degree in Mechanical Engineering, he continued his PhD studies in Robotics at the Vienna University of Technology. Here he worked as a robotic researcher with the university's Intelligent Manufacturing Systems Group as well as a guest researcher at various European universities, including the Swiss Federal Institute of Technology Lausanne (EPFL). During this time he published more than 20 scientific papers, gave presentations, served as a reviewer for major robotic journals and conferences and most importantly he co-founded and built the International Journal of Advanced Robotic Systems- world's first Open Access journal in the field of robotics. Starting this journal was a pivotal point in his career, since it was a pathway to founding IntechOpen - Open Access publisher focused on addressing academic researchers needs. Alex is a personification of IntechOpen key values being trusted, open and entrepreneurial. Today his focus is on defining the growth and development strategy for the company.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"19816",title:"Prof.",name:"Alexander",middleName:null,surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/19816/images/1607_n.jpg",biography:"Alexander I. Kokorin: born: 1947, Moscow; DSc., PhD; Principal Research Fellow (Research Professor) of Department of Kinetics and Catalysis, N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow.\r\nArea of research interests: physical chemistry of complex-organized molecular and nanosized systems, including polymer-metal complexes; the surface of doped oxide semiconductors. He is an expert in structural, absorptive, catalytic and photocatalytic properties, in structural organization and dynamic features of ionic liquids, in magnetic interactions between paramagnetic centers. The author or co-author of 3 books, over 200 articles and reviews in scientific journals and books. He is an actual member of the International EPR/ESR Society, European Society on Quantum Solar Energy Conversion, Moscow House of Scientists, of the Board of Moscow Physical Society.",institutionString:null,institution:{name:"Semenov Institute of Chemical Physics",country:{name:"Russia"}}},{id:"62389",title:"PhD.",name:"Ali Demir",middleName:null,surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/62389/images/3413_n.jpg",biography:"Dr. Ali Demir Sezer has a Ph.D. from Pharmaceutical Biotechnology at the Faculty of Pharmacy, University of Marmara (Turkey). He is the member of many Pharmaceutical Associations and acts as a reviewer of scientific journals and European projects under different research areas such as: drug delivery systems, nanotechnology and pharmaceutical biotechnology. Dr. Sezer is the author of many scientific publications in peer-reviewed journals and poster communications. Focus of his research activity is drug delivery, physico-chemical characterization and biological evaluation of biopolymers micro and nanoparticles as modified drug delivery system, and colloidal drug carriers (liposomes, nanoparticles etc.).",institutionString:null,institution:{name:"Marmara University",country:{name:"Turkey"}}},{id:"61051",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"100762",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"St David's Medical Center",country:{name:"United States of America"}}},{id:"107416",title:"Dr.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Texas Cardiac Arrhythmia",country:{name:"United States of America"}}},{id:"64434",title:"Dr.",name:"Angkoon",middleName:null,surname:"Phinyomark",slug:"angkoon-phinyomark",fullName:"Angkoon Phinyomark",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/64434/images/2619_n.jpg",biography:"My name is Angkoon Phinyomark. I received a B.Eng. degree in Computer Engineering with First Class Honors in 2008 from Prince of Songkla University, Songkhla, Thailand, where I received a Ph.D. degree in Electrical Engineering. My research interests are primarily in the area of biomedical signal processing and classification notably EMG (electromyography signal), EOG (electrooculography signal), and EEG (electroencephalography signal), image analysis notably breast cancer analysis and optical coherence tomography, and rehabilitation engineering. I became a student member of IEEE in 2008. During October 2011-March 2012, I had worked at School of Computer Science and Electronic Engineering, University of Essex, Colchester, Essex, United Kingdom. In addition, during a B.Eng. I had been a visiting research student at Faculty of Computer Science, University of Murcia, Murcia, Spain for three months.\n\nI have published over 40 papers during 5 years in refereed journals, books, and conference proceedings in the areas of electro-physiological signals processing and classification, notably EMG and EOG signals, fractal analysis, wavelet analysis, texture analysis, feature extraction and machine learning algorithms, and assistive and rehabilitative devices. I have several computer programming language certificates, i.e. Sun Certified Programmer for the Java 2 Platform 1.4 (SCJP), Microsoft Certified Professional Developer, Web Developer (MCPD), Microsoft Certified Technology Specialist, .NET Framework 2.0 Web (MCTS). I am a Reviewer for several refereed journals and international conferences, such as IEEE Transactions on Biomedical Engineering, IEEE Transactions on Industrial Electronics, Optic Letters, Measurement Science Review, and also a member of the International Advisory Committee for 2012 IEEE Business Engineering and Industrial Applications and 2012 IEEE Symposium on Business, Engineering and Industrial Applications.",institutionString:null,institution:{name:"Joseph Fourier University",country:{name:"France"}}},{id:"55578",title:"Dr.",name:"Antonio",middleName:null,surname:"Jurado-Navas",slug:"antonio-jurado-navas",fullName:"Antonio Jurado-Navas",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/55578/images/4574_n.png",biography:"Antonio Jurado-Navas received the M.S. degree (2002) and the Ph.D. degree (2009) in Telecommunication Engineering, both from the University of Málaga (Spain). He first worked as a consultant at Vodafone-Spain. From 2004 to 2011, he was a Research Assistant with the Communications Engineering Department at the University of Málaga. In 2011, he became an Assistant Professor in the same department. From 2012 to 2015, he was with Ericsson Spain, where he was working on geo-location\ntools for third generation mobile networks. Since 2015, he is a Marie-Curie fellow at the Denmark Technical University. His current research interests include the areas of mobile communication systems and channel modeling in addition to atmospheric optical communications, adaptive optics and statistics",institutionString:null,institution:{name:"University of Malaga",country:{name:"Spain"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5681},{group:"region",caption:"Middle and South America",value:2,count:5161},{group:"region",caption:"Africa",value:3,count:1683},{group:"region",caption:"Asia",value:4,count:10200},{group:"region",caption:"Australia and Oceania",value:5,count:886},{group:"region",caption:"Europe",value:6,count:15610}],offset:12,limit:12,total:117096},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{sort:"dateendthirdsteppublish"},books:[],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:9},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:18},{group:"topic",caption:"Business, Management and Economics",value:7,count:2},{group:"topic",caption:"Chemistry",value:8,count:7},{group:"topic",caption:"Computer and Information Science",value:9,count:10},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:5},{group:"topic",caption:"Engineering",value:11,count:14},{group:"topic",caption:"Environmental Sciences",value:12,count:2},{group:"topic",caption:"Immunology and Microbiology",value:13,count:5},{group:"topic",caption:"Materials Science",value:14,count:4},{group:"topic",caption:"Mathematics",value:15,count:1},{group:"topic",caption:"Medicine",value:16,count:63},{group:"topic",caption:"Nanotechnology and Nanomaterials",value:17,count:1},{group:"topic",caption:"Neuroscience",value:18,count:1},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:6},{group:"topic",caption:"Physics",value:20,count:2},{group:"topic",caption:"Psychology",value:21,count:3},{group:"topic",caption:"Robotics",value:22,count:1},{group:"topic",caption:"Social Sciences",value:23,count:3},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:2}],offset:0,limit:12,total:null},popularBooks:{featuredBooks:[{type:"book",id:"9208",title:"Welding",subtitle:"Modern Topics",isOpenForSubmission:!1,hash:"7d6be076ccf3a3f8bd2ca52d86d4506b",slug:"welding-modern-topics",bookSignature:"Sadek Crisóstomo Absi Alfaro, Wojciech Borek and Błażej Tomiczek",coverURL:"https://cdn.intechopen.com/books/images_new/9208.jpg",editors:[{id:"65292",title:"Prof.",name:"Sadek Crisostomo Absi",middleName:"C. Absi",surname:"Alfaro",slug:"sadek-crisostomo-absi-alfaro",fullName:"Sadek Crisostomo Absi Alfaro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9139",title:"Topics in Primary Care Medicine",subtitle:null,isOpenForSubmission:!1,hash:"ea774a4d4c1179da92a782e0ae9cde92",slug:"topics-in-primary-care-medicine",bookSignature:"Thomas F. Heston",coverURL:"https://cdn.intechopen.com/books/images_new/9139.jpg",editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8697",title:"Virtual Reality and Its Application in Education",subtitle:null,isOpenForSubmission:!1,hash:"ee01b5e387ba0062c6b0d1e9227bda05",slug:"virtual-reality-and-its-application-in-education",bookSignature:"Dragan Cvetković",coverURL:"https://cdn.intechopen.com/books/images_new/8697.jpg",editors:[{id:"101330",title:"Dr.",name:"Dragan",middleName:"Mladen",surname:"Cvetković",slug:"dragan-cvetkovic",fullName:"Dragan Cvetković"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9785",title:"Endometriosis",subtitle:null,isOpenForSubmission:!1,hash:"f457ca61f29cf7e8bc191732c50bb0ce",slug:"endometriosis",bookSignature:"Courtney Marsh",coverURL:"https://cdn.intechopen.com/books/images_new/9785.jpg",editors:[{id:"255491",title:"Dr.",name:"Courtney",middleName:null,surname:"Marsh",slug:"courtney-marsh",fullName:"Courtney Marsh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9343",title:"Trace Metals in the Environment",subtitle:"New Approaches and Recent Advances",isOpenForSubmission:!1,hash:"ae07e345bc2ce1ebbda9f70c5cd12141",slug:"trace-metals-in-the-environment-new-approaches-and-recent-advances",bookSignature:"Mario Alfonso Murillo-Tovar, Hugo Saldarriaga-Noreña and Agnieszka Saeid",coverURL:"https://cdn.intechopen.com/books/images_new/9343.jpg",editors:[{id:"255959",title:"Dr.",name:"Mario Alfonso",middleName:null,surname:"Murillo-Tovar",slug:"mario-alfonso-murillo-tovar",fullName:"Mario Alfonso Murillo-Tovar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7831",title:"Sustainability in Urban Planning and Design",subtitle:null,isOpenForSubmission:!1,hash:"c924420492c8c2c9751e178d025f4066",slug:"sustainability-in-urban-planning-and-design",bookSignature:"Amjad Almusaed, Asaad Almssad and Linh Truong - Hong",coverURL:"https://cdn.intechopen.com/books/images_new/7831.jpg",editors:[{id:"110471",title:"Dr.",name:"Amjad",middleName:"Zaki",surname:"Almusaed",slug:"amjad-almusaed",fullName:"Amjad Almusaed"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8468",title:"Sheep Farming",subtitle:"An Approach to Feed, Growth and Sanity",isOpenForSubmission:!1,hash:"838f08594850bc04aa14ec873ed1b96f",slug:"sheep-farming-an-approach-to-feed-growth-and-sanity",bookSignature:"António Monteiro",coverURL:"https://cdn.intechopen.com/books/images_new/8468.jpg",editors:[{id:"190314",title:"Prof.",name:"António",middleName:"Cardoso",surname:"Monteiro",slug:"antonio-monteiro",fullName:"António Monteiro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8816",title:"Financial Crises",subtitle:"A Selection of Readings",isOpenForSubmission:!1,hash:"6f2f49fb903656e4e54280c79fabd10c",slug:"financial-crises-a-selection-of-readings",bookSignature:"Stelios Markoulis",coverURL:"https://cdn.intechopen.com/books/images_new/8816.jpg",editors:[{id:"237863",title:"Dr.",name:"Stelios",middleName:null,surname:"Markoulis",slug:"stelios-markoulis",fullName:"Stelios Markoulis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9376",title:"Contemporary Developments and Perspectives in International Health Security",subtitle:"Volume 1",isOpenForSubmission:!1,hash:"b9a00b84cd04aae458fb1d6c65795601",slug:"contemporary-developments-and-perspectives-in-international-health-security-volume-1",bookSignature:"Stanislaw P. Stawicki, Michael S. Firstenberg, Sagar C. Galwankar, Ricardo Izurieta and Thomas Papadimos",coverURL:"https://cdn.intechopen.com/books/images_new/9376.jpg",editors:[{id:"181694",title:"Dr.",name:"Stanislaw P.",middleName:null,surname:"Stawicki",slug:"stanislaw-p.-stawicki",fullName:"Stanislaw P. Stawicki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7769",title:"Medical Isotopes",subtitle:null,isOpenForSubmission:!1,hash:"f8d3c5a6c9a42398e56b4e82264753f7",slug:"medical-isotopes",bookSignature:"Syed Ali Raza Naqvi and Muhammad Babar Imrani",coverURL:"https://cdn.intechopen.com/books/images_new/7769.jpg",editors:[{id:"259190",title:"Dr.",name:"Syed Ali Raza",middleName:null,surname:"Naqvi",slug:"syed-ali-raza-naqvi",fullName:"Syed Ali Raza Naqvi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9279",title:"Concepts, Applications and Emerging Opportunities in Industrial Engineering",subtitle:null,isOpenForSubmission:!1,hash:"9bfa87f9b627a5468b7c1e30b0eea07a",slug:"concepts-applications-and-emerging-opportunities-in-industrial-engineering",bookSignature:"Gary Moynihan",coverURL:"https://cdn.intechopen.com/books/images_new/9279.jpg",editors:[{id:"16974",title:"Dr.",name:"Gary",middleName:null,surname:"Moynihan",slug:"gary-moynihan",fullName:"Gary Moynihan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7807",title:"A Closer Look at Organizational Culture in Action",subtitle:null,isOpenForSubmission:!1,hash:"05c608b9271cc2bc711f4b28748b247b",slug:"a-closer-look-at-organizational-culture-in-action",bookSignature:"Süleyman Davut Göker",coverURL:"https://cdn.intechopen.com/books/images_new/7807.jpg",editors:[{id:"190035",title:"Associate Prof.",name:"Süleyman Davut",middleName:null,surname:"Göker",slug:"suleyman-davut-goker",fullName:"Süleyman Davut Göker"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:5126},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"9208",title:"Welding",subtitle:"Modern Topics",isOpenForSubmission:!1,hash:"7d6be076ccf3a3f8bd2ca52d86d4506b",slug:"welding-modern-topics",bookSignature:"Sadek Crisóstomo Absi Alfaro, Wojciech Borek and Błażej Tomiczek",coverURL:"https://cdn.intechopen.com/books/images_new/9208.jpg",editors:[{id:"65292",title:"Prof.",name:"Sadek Crisostomo Absi",middleName:"C. Absi",surname:"Alfaro",slug:"sadek-crisostomo-absi-alfaro",fullName:"Sadek Crisostomo Absi Alfaro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9139",title:"Topics in Primary Care Medicine",subtitle:null,isOpenForSubmission:!1,hash:"ea774a4d4c1179da92a782e0ae9cde92",slug:"topics-in-primary-care-medicine",bookSignature:"Thomas F. Heston",coverURL:"https://cdn.intechopen.com/books/images_new/9139.jpg",editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8697",title:"Virtual Reality and Its Application in Education",subtitle:null,isOpenForSubmission:!1,hash:"ee01b5e387ba0062c6b0d1e9227bda05",slug:"virtual-reality-and-its-application-in-education",bookSignature:"Dragan Cvetković",coverURL:"https://cdn.intechopen.com/books/images_new/8697.jpg",editors:[{id:"101330",title:"Dr.",name:"Dragan",middleName:"Mladen",surname:"Cvetković",slug:"dragan-cvetkovic",fullName:"Dragan Cvetković"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9785",title:"Endometriosis",subtitle:null,isOpenForSubmission:!1,hash:"f457ca61f29cf7e8bc191732c50bb0ce",slug:"endometriosis",bookSignature:"Courtney Marsh",coverURL:"https://cdn.intechopen.com/books/images_new/9785.jpg",editors:[{id:"255491",title:"Dr.",name:"Courtney",middleName:null,surname:"Marsh",slug:"courtney-marsh",fullName:"Courtney Marsh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9343",title:"Trace Metals in the Environment",subtitle:"New Approaches and Recent Advances",isOpenForSubmission:!1,hash:"ae07e345bc2ce1ebbda9f70c5cd12141",slug:"trace-metals-in-the-environment-new-approaches-and-recent-advances",bookSignature:"Mario Alfonso Murillo-Tovar, Hugo Saldarriaga-Noreña and Agnieszka Saeid",coverURL:"https://cdn.intechopen.com/books/images_new/9343.jpg",editors:[{id:"255959",title:"Dr.",name:"Mario Alfonso",middleName:null,surname:"Murillo-Tovar",slug:"mario-alfonso-murillo-tovar",fullName:"Mario Alfonso Murillo-Tovar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8468",title:"Sheep Farming",subtitle:"An Approach to Feed, Growth and Sanity",isOpenForSubmission:!1,hash:"838f08594850bc04aa14ec873ed1b96f",slug:"sheep-farming-an-approach-to-feed-growth-and-sanity",bookSignature:"António Monteiro",coverURL:"https://cdn.intechopen.com/books/images_new/8468.jpg",editors:[{id:"190314",title:"Prof.",name:"António",middleName:"Cardoso",surname:"Monteiro",slug:"antonio-monteiro",fullName:"António Monteiro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8816",title:"Financial Crises",subtitle:"A Selection of Readings",isOpenForSubmission:!1,hash:"6f2f49fb903656e4e54280c79fabd10c",slug:"financial-crises-a-selection-of-readings",bookSignature:"Stelios Markoulis",coverURL:"https://cdn.intechopen.com/books/images_new/8816.jpg",editors:[{id:"237863",title:"Dr.",name:"Stelios",middleName:null,surname:"Markoulis",slug:"stelios-markoulis",fullName:"Stelios Markoulis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7831",title:"Sustainability in Urban Planning and Design",subtitle:null,isOpenForSubmission:!1,hash:"c924420492c8c2c9751e178d025f4066",slug:"sustainability-in-urban-planning-and-design",bookSignature:"Amjad Almusaed, Asaad Almssad and Linh Truong - Hong",coverURL:"https://cdn.intechopen.com/books/images_new/7831.jpg",editors:[{id:"110471",title:"Dr.",name:"Amjad",middleName:"Zaki",surname:"Almusaed",slug:"amjad-almusaed",fullName:"Amjad Almusaed"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9376",title:"Contemporary Developments and Perspectives in International Health Security",subtitle:"Volume 1",isOpenForSubmission:!1,hash:"b9a00b84cd04aae458fb1d6c65795601",slug:"contemporary-developments-and-perspectives-in-international-health-security-volume-1",bookSignature:"Stanislaw P. Stawicki, Michael S. Firstenberg, Sagar C. Galwankar, Ricardo Izurieta and Thomas Papadimos",coverURL:"https://cdn.intechopen.com/books/images_new/9376.jpg",editors:[{id:"181694",title:"Dr.",name:"Stanislaw P.",middleName:null,surname:"Stawicki",slug:"stanislaw-p.-stawicki",fullName:"Stanislaw P. Stawicki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7769",title:"Medical Isotopes",subtitle:null,isOpenForSubmission:!1,hash:"f8d3c5a6c9a42398e56b4e82264753f7",slug:"medical-isotopes",bookSignature:"Syed Ali Raza Naqvi and Muhammad Babar Imrani",coverURL:"https://cdn.intechopen.com/books/images_new/7769.jpg",editors:[{id:"259190",title:"Dr.",name:"Syed Ali Raza",middleName:null,surname:"Naqvi",slug:"syed-ali-raza-naqvi",fullName:"Syed Ali Raza Naqvi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"8468",title:"Sheep Farming",subtitle:"An Approach to Feed, Growth and Health",isOpenForSubmission:!1,hash:"838f08594850bc04aa14ec873ed1b96f",slug:"sheep-farming-an-approach-to-feed-growth-and-health",bookSignature:"António Monteiro",coverURL:"https://cdn.intechopen.com/books/images_new/8468.jpg",editedByType:"Edited by",editors:[{id:"190314",title:"Prof.",name:"António",middleName:"Cardoso",surname:"Monteiro",slug:"antonio-monteiro",fullName:"António Monteiro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9523",title:"Oral and Maxillofacial Surgery",subtitle:null,isOpenForSubmission:!1,hash:"5eb6ec2db961a6c8965d11180a58d5c1",slug:"oral-and-maxillofacial-surgery",bookSignature:"Gokul Sridharan",coverURL:"https://cdn.intechopen.com/books/images_new/9523.jpg",editedByType:"Edited by",editors:[{id:"82453",title:"Dr.",name:"Gokul",middleName:null,surname:"Sridharan",slug:"gokul-sridharan",fullName:"Gokul Sridharan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9785",title:"Endometriosis",subtitle:null,isOpenForSubmission:!1,hash:"f457ca61f29cf7e8bc191732c50bb0ce",slug:"endometriosis",bookSignature:"Courtney Marsh",coverURL:"https://cdn.intechopen.com/books/images_new/9785.jpg",editedByType:"Edited by",editors:[{id:"255491",title:"Dr.",name:"Courtney",middleName:null,surname:"Marsh",slug:"courtney-marsh",fullName:"Courtney Marsh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9018",title:"Some RNA Viruses",subtitle:null,isOpenForSubmission:!1,hash:"a5cae846dbe3692495fc4add2f60fd84",slug:"some-rna-viruses",bookSignature:"Yogendra Shah and Eltayb Abuelzein",coverURL:"https://cdn.intechopen.com/books/images_new/9018.jpg",editedByType:"Edited by",editors:[{id:"278914",title:"Ph.D.",name:"Yogendra",middleName:null,surname:"Shah",slug:"yogendra-shah",fullName:"Yogendra Shah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8816",title:"Financial Crises",subtitle:"A Selection of Readings",isOpenForSubmission:!1,hash:"6f2f49fb903656e4e54280c79fabd10c",slug:"financial-crises-a-selection-of-readings",bookSignature:"Stelios Markoulis",coverURL:"https://cdn.intechopen.com/books/images_new/8816.jpg",editedByType:"Edited by",editors:[{id:"237863",title:"Dr.",name:"Stelios",middleName:null,surname:"Markoulis",slug:"stelios-markoulis",fullName:"Stelios Markoulis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9585",title:"Advances in Complex Valvular Disease",subtitle:null,isOpenForSubmission:!1,hash:"ef64f11e211621ecfe69c46e60e7ca3d",slug:"advances-in-complex-valvular-disease",bookSignature:"Michael S. Firstenberg and Imran Khan",coverURL:"https://cdn.intechopen.com/books/images_new/9585.jpg",editedByType:"Edited by",editors:[{id:"64343",title:null,name:"Michael S.",middleName:"S",surname:"Firstenberg",slug:"michael-s.-firstenberg",fullName:"Michael S. Firstenberg"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10150",title:"Smart Manufacturing",subtitle:"When Artificial Intelligence Meets the Internet of Things",isOpenForSubmission:!1,hash:"87004a19de13702d042f8ff96d454698",slug:"smart-manufacturing-when-artificial-intelligence-meets-the-internet-of-things",bookSignature:"Tan Yen Kheng",coverURL:"https://cdn.intechopen.com/books/images_new/10150.jpg",editedByType:"Edited by",editors:[{id:"78857",title:"Dr.",name:"Tan Yen",middleName:null,surname:"Kheng",slug:"tan-yen-kheng",fullName:"Tan Yen Kheng"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9386",title:"Direct Numerical Simulations",subtitle:"An Introduction and Applications",isOpenForSubmission:!1,hash:"158a3a0fdba295d21ff23326f5a072d5",slug:"direct-numerical-simulations-an-introduction-and-applications",bookSignature:"Srinivasa Rao",coverURL:"https://cdn.intechopen.com/books/images_new/9386.jpg",editedByType:"Edited by",editors:[{id:"6897",title:"Dr.",name:"Srinivasa",middleName:"P",surname:"Rao",slug:"srinivasa-rao",fullName:"Srinivasa Rao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9139",title:"Topics in Primary Care Medicine",subtitle:null,isOpenForSubmission:!1,hash:"ea774a4d4c1179da92a782e0ae9cde92",slug:"topics-in-primary-care-medicine",bookSignature:"Thomas F. Heston",coverURL:"https://cdn.intechopen.com/books/images_new/9139.jpg",editedByType:"Edited by",editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9208",title:"Welding",subtitle:"Modern Topics",isOpenForSubmission:!1,hash:"7d6be076ccf3a3f8bd2ca52d86d4506b",slug:"welding-modern-topics",bookSignature:"Sadek Crisóstomo Absi Alfaro, Wojciech Borek and Błażej Tomiczek",coverURL:"https://cdn.intechopen.com/books/images_new/9208.jpg",editedByType:"Edited by",editors:[{id:"65292",title:"Prof.",name:"Sadek Crisostomo Absi",middleName:"C. Absi",surname:"Alfaro",slug:"sadek-crisostomo-absi-alfaro",fullName:"Sadek Crisostomo Absi Alfaro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"636",title:"Landscape",slug:"landscape",parent:{title:"Geography",slug:"geography"},numberOfBooks:2,numberOfAuthorsAndEditors:72,numberOfWosCitations:32,numberOfCrossrefCitations:27,numberOfDimensionsCitations:83,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"landscape",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"6396",title:"Urban Agglomeration",subtitle:null,isOpenForSubmission:!1,hash:"da1643c7ce5482ec846a188d34ce2839",slug:"urban-agglomeration",bookSignature:"Mustafa Ergen",coverURL:"https://cdn.intechopen.com/books/images_new/6396.jpg",editedByType:"Edited by",editors:[{id:"166961",title:"Dr.Ing.",name:"Mustafa",middleName:null,surname:"Ergen",slug:"mustafa-ergen",fullName:"Mustafa Ergen"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3727",title:"Land Applications of Radar Remote Sensing",subtitle:null,isOpenForSubmission:!1,hash:"26e11b6e4cce4e245e6e28b281563139",slug:"land-applications-of-radar-remote-sensing",bookSignature:"Francesco Holecz, Paolo Pasquali, Nada Milisavljevic and Damien Closson",coverURL:"https://cdn.intechopen.com/books/images_new/3727.jpg",editedByType:"Edited by",editors:[{id:"13897",title:"Dr.",name:"Damien",middleName:null,surname:"Closson",slug:"damien-closson",fullName:"Damien Closson"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:2,mostCitedChapters:[{id:"57824",doi:"10.5772/intechopen.72047",title:"Waste in the City: Challenges and Opportunities for Urban Agglomerations",slug:"waste-in-the-city-challenges-and-opportunities-for-urban-agglomerations",totalDownloads:1751,totalCrossrefCites:5,totalDimensionsCites:13,book:{slug:"urban-agglomeration",title:"Urban Agglomeration",fullTitle:"Urban Agglomeration"},signatures:"Jutta Gutberlet",authors:[{id:"188532",title:"Prof.",name:"Jutta",middleName:null,surname:"Gutberlet",slug:"jutta-gutberlet",fullName:"Jutta Gutberlet"}]},{id:"58196",doi:"10.5772/intechopen.72191",title:"The Multivariated Effect of City Cooperation in Land Use Planning and Decision-Making Processes: A European Analysis",slug:"the-multivariated-effect-of-city-cooperation-in-land-use-planning-and-decision-making-processes-a-eu",totalDownloads:506,totalCrossrefCites:0,totalDimensionsCites:9,book:{slug:"urban-agglomeration",title:"Urban Agglomeration",fullTitle:"Urban Agglomeration"},signatures:"Luís Carlos Loures, Rui Alexandre Castanho, José Manuel Naranjo\nGómez, Ana Vulevic, José Cabezas and Luis Fernández-Pozo",authors:[{id:"108118",title:"Dr.",name:"Luis",middleName:null,surname:"Loures",slug:"luis-loures",fullName:"Luis Loures"},{id:"215340",title:"Dr.",name:"Ana",middleName:null,surname:"Vulevic",slug:"ana-vulevic",fullName:"Ana Vulevic"},{id:"215341",title:"Prof.",name:"José",middleName:null,surname:"Cabezas Fernández",slug:"jose-cabezas-fernandez",fullName:"José Cabezas Fernández"},{id:"215342",title:"Prof.",name:"José Manuel",middleName:null,surname:"Naranjo Gómez",slug:"jose-manuel-naranjo-gomez",fullName:"José Manuel Naranjo Gómez"},{id:"222742",title:"Dr.",name:"Luis",middleName:null,surname:"Fernández-Pozo",slug:"luis-fernandez-pozo",fullName:"Luis Fernández-Pozo"},{id:"290571",title:"Dr.",name:"Rui Alexandre",middleName:null,surname:"Castanho",slug:"rui-alexandre-castanho",fullName:"Rui Alexandre Castanho"}]},{id:"46357",doi:"10.5772/58220",title:"Large Scale Mapping of Forests and Land Cover with Synthetic Aperture Radar Data",slug:"large-scale-mapping-of-forests-and-land-cover-with-synthetic-aperture-radar-data",totalDownloads:3551,totalCrossrefCites:4,totalDimensionsCites:9,book:{slug:"land-applications-of-radar-remote-sensing",title:"Land Applications of Radar Remote Sensing",fullTitle:"Land Applications of Radar Remote Sensing"},signatures:"Josef Kellndorfer, Oliver Cartus, Jesse Bishop, Wayne Walker and\nFrancesco Holecz",authors:[{id:"168830",title:"Dr.",name:"Francesco",middleName:null,surname:"Holecz",slug:"francesco-holecz",fullName:"Francesco Holecz"},{id:"170758",title:"Dr.",name:"Josef",middleName:null,surname:"Kellndorfer",slug:"josef-kellndorfer",fullName:"Josef Kellndorfer"}]}],mostDownloadedChaptersLast30Days:[{id:"57824",title:"Waste in the City: Challenges and Opportunities for Urban Agglomerations",slug:"waste-in-the-city-challenges-and-opportunities-for-urban-agglomerations",totalDownloads:1751,totalCrossrefCites:5,totalDimensionsCites:13,book:{slug:"urban-agglomeration",title:"Urban Agglomeration",fullTitle:"Urban Agglomeration"},signatures:"Jutta Gutberlet",authors:[{id:"188532",title:"Prof.",name:"Jutta",middleName:null,surname:"Gutberlet",slug:"jutta-gutberlet",fullName:"Jutta Gutberlet"}]},{id:"46448",title:"Mapping of Ground Deformations with Interferometric Stacking Techniques",slug:"mapping-of-ground-deformations-with-interferometric-stacking-techniques",totalDownloads:3142,totalCrossrefCites:4,totalDimensionsCites:9,book:{slug:"land-applications-of-radar-remote-sensing",title:"Land Applications of Radar Remote Sensing",fullTitle:"Land Applications of Radar Remote Sensing"},signatures:"Paolo Pasquali, Alessio Cantone, Paolo Riccardi, Marco Defilippi,\nFumitaka Ogushi, Stefano Gagliano and Masayuki Tamura",authors:[{id:"168247",title:"Dr.",name:"Paolo",middleName:null,surname:"Pasquali",slug:"paolo-pasquali",fullName:"Paolo Pasquali"},{id:"168811",title:"Mr.",name:"Paolo",middleName:null,surname:"Riccardi",slug:"paolo-riccardi",fullName:"Paolo Riccardi"},{id:"168812",title:"Mr.",name:"Alessio",middleName:null,surname:"Cantone",slug:"alessio-cantone",fullName:"Alessio Cantone"},{id:"168813",title:"Mr.",name:"Marco",middleName:null,surname:"Defilippi",slug:"marco-defilippi",fullName:"Marco Defilippi"},{id:"168814",title:"Mr.",name:"Fumitaka",middleName:null,surname:"Ogushi",slug:"fumitaka-ogushi",fullName:"Fumitaka Ogushi"},{id:"168815",title:"Mr.",name:"Stefano",middleName:null,surname:"Gagliano",slug:"stefano-gagliano",fullName:"Stefano Gagliano"},{id:"170671",title:"Prof.",name:"Masayuki",middleName:null,surname:"Tamura",slug:"masayuki-tamura",fullName:"Masayuki Tamura"}]},{id:"57969",title:"The City as an Experimental Space: The Interface between Public Satisfaction and Effects on Urban Planning Resulting from Kampala City’s Sprawl",slug:"the-city-as-an-experimental-space-the-interface-between-public-satisfaction-and-effects-on-urban-pla",totalDownloads:607,totalCrossrefCites:1,totalDimensionsCites:2,book:{slug:"urban-agglomeration",title:"Urban Agglomeration",fullTitle:"Urban Agglomeration"},signatures:"Fred Bidandi",authors:[{id:"215494",title:"Dr.",name:"Fred",middleName:null,surname:"Bidandi",slug:"fred-bidandi",fullName:"Fred Bidandi"}]},{id:"46357",title:"Large Scale Mapping of Forests and Land Cover with Synthetic Aperture Radar Data",slug:"large-scale-mapping-of-forests-and-land-cover-with-synthetic-aperture-radar-data",totalDownloads:3551,totalCrossrefCites:4,totalDimensionsCites:9,book:{slug:"land-applications-of-radar-remote-sensing",title:"Land Applications of Radar Remote Sensing",fullTitle:"Land Applications of Radar Remote Sensing"},signatures:"Josef Kellndorfer, Oliver Cartus, Jesse Bishop, Wayne Walker and\nFrancesco Holecz",authors:[{id:"168830",title:"Dr.",name:"Francesco",middleName:null,surname:"Holecz",slug:"francesco-holecz",fullName:"Francesco Holecz"},{id:"170758",title:"Dr.",name:"Josef",middleName:null,surname:"Kellndorfer",slug:"josef-kellndorfer",fullName:"Josef Kellndorfer"}]},{id:"58749",title:"Wicked Water Systems: A Review of Challenges and Opportunities",slug:"wicked-water-systems-a-review-of-challenges-and-opportunities",totalDownloads:666,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"urban-agglomeration",title:"Urban Agglomeration",fullTitle:"Urban Agglomeration"},signatures:"Tamara Anna Streefland and Yoram Krozer",authors:[{id:"215531",title:"M.Sc.",name:"Tamara",middleName:null,surname:"Streefland",slug:"tamara-streefland",fullName:"Tamara Streefland"},{id:"215532",title:"Dr.",name:"Yoram",middleName:null,surname:"Krozer",slug:"yoram-krozer",fullName:"Yoram Krozer"}]},{id:"46372",title:"High Resolution Radargrammetry – 3D Terrain Modeling",slug:"high-resolution-radargrammetry-3d-terrain-modeling",totalDownloads:3206,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"land-applications-of-radar-remote-sensing",title:"Land Applications of Radar Remote Sensing",fullTitle:"Land Applications of Radar Remote Sensing"},signatures:"Paola Capaldo, Francesca Fratarcangeli, Andrea Nascetti, Francesca\nPieralice, Martina Porfiri and Mattia Crespi",authors:[{id:"168800",title:"Dr.",name:"Mattia",middleName:null,surname:"Crespi",slug:"mattia-crespi",fullName:"Mattia Crespi"},{id:"168825",title:"Dr.",name:"Paola",middleName:null,surname:"Capaldo",slug:"paola-capaldo",fullName:"Paola Capaldo"},{id:"168826",title:"Dr.",name:"Andrea",middleName:null,surname:"Nascetti",slug:"andrea-nascetti",fullName:"Andrea Nascetti"},{id:"168827",title:"MSc.",name:"Martina",middleName:null,surname:"Porfiri",slug:"martina-porfiri",fullName:"Martina Porfiri"},{id:"168828",title:"Dr.",name:"Francesca",middleName:null,surname:"Fratarcangeli",slug:"francesca-fratarcangeli",fullName:"Francesca Fratarcangeli"},{id:"168829",title:"Dr.",name:"Francesca",middleName:null,surname:"Pieralice",slug:"francesca-pieralice",fullName:"Francesca Pieralice"}]},{id:"58109",title:"Urban Agglomeration and Supporting Capacity: The Role of Open Spaces within Urban Drainage Systems as a Structuring Condition for Urban Growth",slug:"urban-agglomeration-and-supporting-capacity-the-role-of-open-spaces-within-urban-drainage-systems-as",totalDownloads:787,totalCrossrefCites:1,totalDimensionsCites:7,book:{slug:"urban-agglomeration",title:"Urban Agglomeration",fullTitle:"Urban Agglomeration"},signatures:"Marcelo Gomes Miguez, Aline Pires Veról, Andréa Queiroz da Silva\nFonseca Rêgo and Ianic Bigate Lourenço",authors:[{id:"97645",title:"Prof.",name:"Marcelo",middleName:"Gomes",surname:"Miguez",slug:"marcelo-miguez",fullName:"Marcelo Miguez"},{id:"215719",title:"Prof.",name:"Aline",middleName:null,surname:"Pires Veról",slug:"aline-pires-verol",fullName:"Aline Pires Veról"},{id:"215720",title:"Prof.",name:"Andréa",middleName:null,surname:"Queiroz Rêgo",slug:"andrea-queiroz-rego",fullName:"Andréa Queiroz Rêgo"},{id:"215721",title:"MSc.",name:"Ianic",middleName:null,surname:"Bigate Lourenço",slug:"ianic-bigate-lourenco",fullName:"Ianic Bigate Lourenço"}]},{id:"46527",title:"Estimation of Cultivated Areas Using Multi-Temporal SAR Data",slug:"estimation-of-cultivated-areas-using-multi-temporal-sar-data",totalDownloads:2390,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"land-applications-of-radar-remote-sensing",title:"Land Applications of Radar Remote Sensing",fullTitle:"Land Applications of Radar Remote Sensing"},signatures:"Nada Milisavljević, Francesco Collivignarelli and Francesco Holecz",authors:[{id:"168830",title:"Dr.",name:"Francesco",middleName:null,surname:"Holecz",slug:"francesco-holecz",fullName:"Francesco Holecz"},{id:"4262",title:"Dr.",name:"Nada",middleName:null,surname:"Milisavljevic",slug:"nada-milisavljevic",fullName:"Nada Milisavljevic"},{id:"168823",title:"MSc.",name:"Francesco",middleName:null,surname:"Collivignarelli",slug:"francesco-collivignarelli",fullName:"Francesco Collivignarelli"}]},{id:"46376",title:"Fusion of Interferometric SAR and Photogrammetric Elevation Data",slug:"fusion-of-interferometric-sar-and-photogrammetric-elevation-data",totalDownloads:2995,totalCrossrefCites:0,totalDimensionsCites:1,book:{slug:"land-applications-of-radar-remote-sensing",title:"Land Applications of Radar Remote Sensing",fullTitle:"Land Applications of Radar Remote Sensing"},signatures:"Loris Copa, Daniela Poli and Fabio Remondino",authors:[{id:"89325",title:"Dr.",name:"Fabio",middleName:null,surname:"Remondino",slug:"fabio-remondino",fullName:"Fabio Remondino"},{id:"168807",title:"M.Sc.",name:"Loris",middleName:null,surname:"Copa",slug:"loris-copa",fullName:"Loris Copa"},{id:"168810",title:"Dr.",name:"Daniela",middleName:null,surname:"Poli",slug:"daniela-poli",fullName:"Daniela Poli"}]},{id:"46344",title:"Dikes Stability Monitoring Versus Sinkholes and Subsidence, Dead Sea Region, Jordan",slug:"dikes-stability-monitoring-versus-sinkholes-and-subsidence-dead-sea-region-jordan",totalDownloads:3110,totalCrossrefCites:3,totalDimensionsCites:8,book:{slug:"land-applications-of-radar-remote-sensing",title:"Land Applications of Radar Remote Sensing",fullTitle:"Land Applications of Radar Remote Sensing"},signatures:"Damien Closson and Najib Abou Karaki",authors:[{id:"13897",title:"Dr.",name:"Damien",middleName:null,surname:"Closson",slug:"damien-closson",fullName:"Damien Closson"},{id:"168785",title:"Prof.",name:"Najib",middleName:null,surname:"Abou Karaki",slug:"najib-abou-karaki",fullName:"Najib Abou Karaki"},{id:"168786",title:"Dr.",name:"Paolo",middleName:null,surname:"Pasquali",slug:"paolo-pasquali",fullName:"Paolo Pasquali"},{id:"168787",title:"Dr.",name:"Paolo",middleName:null,surname:"Riccardi",slug:"paolo-riccardi",fullName:"Paolo Riccardi"}]}],onlineFirstChaptersFilter:{topicSlug:"landscape",limit:3,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"profile.detail",path:"/profiles/163339/andre-augusto-campangnole-dos-santos",hash:"",query:{},params:{id:"163339",slug:"andre-augusto-campangnole-dos-santos"},fullPath:"/profiles/163339/andre-augusto-campangnole-dos-santos",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()